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Results The guidelines consist of five chapters and 
five algorithms. Prior to the first chapter, basic items are 
described including staging classification and history, clas-
sification of histology, and definition of the methods of 
surgery, radiation, and chemotherapy to give the reader a 
better understanding of the contents of the guidelines for 
these rare tumors. The first chapter gives an overview of the 
guidelines, including the basic policy of the guidelines. The 
second chapter discusses vulvar cancer, the third chapter dis-
cusses vaginal cancer, and the fourth chapter discusses vul-
var Paget’s disease and malignant melanoma. Each chapter 
includes clinical questions, recommendations, backgrounds, 
objectives, explanations, and references. The fifth chapter 
provides supplemental data for the drugs that are mentioned 
in the explanation of clinical questions.
Abstract 
Background Vulvar cancer and vaginal cancer are relatively 
rare tumors, and there had been no established treatment 
principles or guidelines to treat these rare tumors in Japan. 
The first version of the Japan Society of Gynecologic Oncol-
ogy (JSGO) guidelines for the treatment of vulvar cancer and 
vaginal cancer was published in 2015 in Japanese.
Objective The JSGO committee decided to publish the 
English version of the JSGO guidelines worldwide, and hope 
it will be a useful guide to physicians in a similar situation 
as in Japan.
Methods The guideline was created according to the basic 
principles in creating the guidelines of JSGO.
Electronic supplementary material The online version of this 
article (doi:10.1007/s10147-017-1193-z) contains supplementary 
material, which is available to authorized users.
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Conclusion Overall, the objective of these guidelines is to 
clearly delineate the standard of care for vulvar and vaginal 
cancer with the goal of ensuring a high standard of care for 
all women diagnosed with these rare diseases.
Keywords Clinical practice guidelines · Vulvar cancer · 
Vaginal cancer · Vulvar Paget’s disease · Malignant 
melanoma of the vulva and vagina · Treatment
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CR  Complete response
CT  Computed tomography
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Treatment of Cancer
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GOG  Gynecologic Oncology Group
HIV  Human immunodeficiency virus
HPV  Human papillomavirus
HSIL  High-grade squamous intraepithelial lesion
IGBT  Image-guided brachytherapy
IMRT  Intensity-modulated radiation therapy
ISSVD  International Society for the Study of Vulvo-
vaginal Disease
JGOG  Japanese Gynecologic Oncology Group
LEEP  Loop electrosurgical excision procedure
LSIL  Low-grade squamous intraepithelial lesion
MRI  Magnetic resonance imaging
NCI  National Cancer Institute
PDT  Photodynamic therapy
PR  Partial response
PS  Performance status
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SLN  Sentinel lymph node
VAIN  Vaginal intraepithelial neoplasia
u/d VIN  Usual/differentiated vulvar intraepithelial 
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WHO  World Health Organization
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Introduction
Although vulvar cancer and vaginal cancer are rare tumors, 
they actually constitute the fourth and fifth most common can-
cers in the gynecologic oncology field. However, there are no 
established treatment principles or guidelines to treat these rare 
tumors in Japan. The Guideline Committee of Japan Society of 
Gynecologic Oncology (JSGO) has established the treatment 
guidelines for cervical cancer and considered further revisions to 
the Guidelines for the Treatment of Cervical Cancer. However, 
as the revised version would include new content about treat-
ment guidelines for vulvar and vaginal cancer that had not been 
made explicit internationally in 2015, it was decided to publish 
a fourth series of JSGO treatment guidelines, the Guidelines for 
the Treatment of Vulvar and Vaginal Cancer, 2015 edition. In the 
course of preparing the guidelines, a period just under 2 years, 
the Committee searched extensively for data on the treatment 
of vulvar and vaginal cancer, both in Japan and internationally, 
and collated the findings. Finally, treatment guidelines that the 
committee felt were most applicable to treatment situations in 
Japan were presented in the form of 16 clinical questions. The 
committee is confident that the guidelines constitute an indis-
pensable resource for healthcare providers engaged in the treat-
ment of vulvar and vaginal cancer, and that their use will lead to 
the best possible outcomes for cancer patients and their families.
The main points of these treatment guidelines are as follows.
1. Clinical questions (CQs) are established with focus on 
vulvar and vaginal cancer, which are epithelial neoplasias. 
Rare malignancies that can be treated by gynecologic oncol-
ogists, such as vulvar Paget’s disease, as well as malignant 
melanomas are also included as objects of consideration. 
To encompass all of these types of cancers, the broad terms 
‘vulvar cancer’ and ‘vaginal cancer’ were adopted.
2. The ‘Basic Items Regarding The Guidelines’ section pro-
vides explanations regarding staging classification, histo-
logical categories, methods of surgical therapies, radiation 
therapies and chemotherapies, to give the reader a better 
understanding of the contents of the guidelines (supplied as 
an Appendix in the present article).
3. The ‘Basic Items’ section provides historical background 
on the classification of staging in vulvar and vaginal cancer. 
It lists the classifications of staging adopted by the JSOG in 
2014 and sets in order the names of lymph nodes and their 
definitions. In addition, in view of the fact that no unique 
classifications of staging have been developed for vulvar 
malignant melanomas, the TNM classifications for cutane-
ous malignant melanomas are adopted with modifications.
4. In histological classifications, because no classifications unique 
to Japan exist, the original texts are provided of the long-used 
2003 World Health Organization (WHO) classifications and the 
new, revised classifications of 2014. An explanation is added 
regarding the differences between these two classification sys-
tems as regards intraepithelial neoplasias of the vulva and vagina.
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5. In surgical therapy and radiation therapy, the terminol-
ogy in Japanese and English are presented side-by-side. For 
surgical therapy, the terminology for generally used excision 
margins and surgical resection stumps is specified.
Following publication of the Japanese guidelines in August 
2015, the NCCN Clinical Practice Guidelines in Oncology 
published the guidelines for vulvar cancer (squamous cell car-
cinoma) version 1.0 on the website in January 2016. Although 
the basic principles were almost identical to the JSGO guide-
lines, differences existed in several points. The major differ-
ence is that the JSGO guidelines include vaginal cancer and 
other diseases in the vulva and vagina, such as Paget’s disease 
and malignant melanoma, and intend to publish for gynecolo-
gists who are not familiar with these rare diseases in Japan. 
The committee decided to publish the English version of the 
JSGO guidelines worldwide, and hope it will be a useful guide 
to physicians in a similar situation in Japan.
Chapter 1: Overview of guidelines
1. How to use these guidelines
The purpose of the guidelines is to indicate one set of standards 
that can be used to select better options in the treatment of vul-
var and vaginal cancer in Japan, and to provide the evidence on 
which those options are based. However, the guidelines are not 
intended to limit the therapies listed. The principal objectives 
of the guidelines are (1) to indicate treatment methods that 
are currently considered appropriate for vulvar and vaginal 
cancer; (2) to minimize variances in the treatment methods 
among institutions; (3) to improve the safety of treatment and 
prognosis of the diseases; (4) to reduce the economic and psy-
chosomatic burden of patients by promoting the performance 
of appropriate treatment; and (5) to enhance mutual under-
standing between patients and healthcare professionals.
2. Intended readers
The guidelines are for the use of all physicians involved in 
the treatment of vulvar and vaginal cancer.
3. Diseases addressed by these guidelines
In the guidelines, the term ‘vulvar and vaginal cancer’ cov-
ers not only epithelial tumors such as vulvar cancer, vaginal 
cancer, but also vulvar Paget’s disease and malignant mela-
nomas of the vulva and vagina.
4. Basic principles in creating the guidelines
To prepare the guidelines, two independent committees, the 
Committee for Drafting of the Guidelines for the Treatment 
of Vulvar and Vaginal Cancer and the Committee for Evalua-
tion of the Guidelines for the Treatment of Vulvar and Vaginal 
Cancer (‘Drafting Committee’ and ‘Evaluation Committee’) 
were established within the Guideline Committee established 
by the JSGO. The first draft of the guidelines was created as 
a result of extensive research by both of these committees. 
Thereafter, the opinions of the Japan Society of Obstetrics and 
Gynecology (JSOG), the Japan Association of Obstetrics and 
Gynecology (JAOG), the Japanese Gynecologic Oncology 
Group (JGOG), the Japanese Society for Radiation Oncol-
ogy (JASTRO), the Japanese Society of Pathology (JSP), 
the Japanese Dermatological Association (JDA), the Japan 
Society of Plastic and Reconstructive Surgery (JSPRS), the 
Japan Society of Clinical Oncology (JSCO) and other related 
academic societies and associations were incorporated into 
the document to produce a final draft. After the final draft 
was circulated among JSGO members and a consensus was 
reached, the JSGO approved the draft for publication.
Most of the evidence adopted in the guidelines was 
obtained from clinical trials conducted in North America, 
Europe and Japan. However, given the differences between 
practices in Japan and other countries, the consensus regard-
ing clinical practice in Japan took priority in the event of 
discrepancies.
In addition, the following general principles guided the 
committee’s drafting policy.
(1) The guidelines were prepared in accordance with the 
procedures of evidence-based medicine, the interna-
tional standard method.
(2) The committee gathered and accumulated evidence 
through extensive perusal of literature and data reported 
throughout Japan and worldwide up to December 2013. 
Where deemed necessary, evidence was also adopted 
from literature and data reported during the drafting 
period of the guidelines, subsequent to December 2013.
(3) The collected evidence was evaluated for quality using 
the criteria of the JSCO and its Formulation Committee 
of Clinical Practice Guidelines for the Use of Antican-
Table 1  Criteria for the 
evaluation of the quality of 
evidence (levels)
Level I Meta-analysis of multiple randomized controlled trials
Level II Randomized controlled trials or well-designed non-randomized controlled trials
Level III Well-designed quasi-experimental studies, comparative studies, correlation studies, case-com-
parison studies or other well-designed non-experimental descriptive studies
Level IV Reports and opinions of specialized committees or clinical experiences of authoritative persons
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cer Agents [1, 2]. However, some of the contents were 
modified in line with these guidelines (Table 1).
(4) The criteria of the strength for the recommendations 
indicated in the guidelines are determined by the crite-
ria for recommendations in JSCO’s Guidelines for the 
Appropriate Use of Anti-cancer Drugs [1, 2] and the 
Minds Handbook on Preparation of Treatment Guide-
lines 2007 [3]. However, some of the content of those 
guidelines have been modified for the purposes of the 
guidelines (Table 2).
(5) Each of the topics in the guidelines consists of a CQ, 
a recommendation, an objective or set of objectives, 
and an explanation. If a more detailed explanation 
is deemed necessary to recommend a treatment, the 
explanation is added in a supplementary note.
(6) At the end of each topic, the literatures which the guide-
line cited were collated in Literature Cited.
(7) Some of the treatment methods evaluated and recom-
mended worldwide are problematic in terms of appli-
cation under Japan’s medical insurance system. In this 
regard, the present guidelines follow the Formulation 
Committee of Clinical Practice Guidelines for the Use 
of Anticancer Agents [1, 2].
5. Disclosure of information
The guidelines are intended to be used widely. Their content 
is published as a booklet and is available for perusal on the 
JSGO website.
6. Responsibility for treatment
The JSGO bears the responsibility for the content and 
description of these guidelines. However, the final decision 
to use these guidelines should be made by the individual 
user. Thus, the responsibility for the treatment outcomes 
should be directly attributed to the person in charge.
7. Revision
(1) These guidelines are continuously being revised by the 
Committee for Treatment Guidelines for Vulvar and 
Vaginal Cancer with medical advances and medical 
changes.
(2) Newly accumulated evidence after publishing these 
guidelines is saved in a database.
(3) Any associated information regarding clinical incon-
venience occurring with the use of these guidelines is 
collected.
(4) Revision work is conducted by the Guidelines Formu-
lation Committee and Evaluation Committee based on 
new evidence and information. Moreover, opinions 
from the associated academic societies, groups or 
JSGO members are widely gained.
(5) After the processes described above, the Drafting Com-
mittee organizes the final revisions to the guidelines, 
and the JSGO approves the draft.
8. Summary of recommendation
In general, each chapter comprises a CQ, recommenda-
tions, background, objectives, explanations, and references. 
This article summarizes these guidelines in a question-and-
answer format. Recommendations from each chapter are 
listed below under their respective chapter titles.
9. Algorithms
These guidelines contain the following 5 algorithms:
1. Primary treatment for vulvar cancer (vulvar tumor and 
inguinal lymph node)
2. Management of inguinal lymph nodes of vulvar cancer
3. Treatment of distant metastasis, recurrent tumor of vul-
var cancer
Table 2  Criteria for 
recommendation (grades)
In addition to the question of evidence, recommendation Grade A can be applied based on judgment on the 
level of general common sense. Because evidence is extremely sparse in the case of rare diseases, recom-
mendation grades are decided based on the judgment of the Drafting Committee
Grade A Action is strongly recommended
In principle at least one Level I item of evidence indicating effectiveness is present
Grade B Action is recommended
In principle at least one Level II item of evidence indicating effectiveness is present
Grade C1 Action may be considered, but scientific grounds are not yet sufficient
(Alternatively, scientific grounds are not yet sufficient, but the possibility exists that effec-
tiveness can be expected)
Multiple Level III items of evidence indicating effectiveness are present, and results are 
generally consistent
Grade C2 Scientific grounds are not sufficient and application in routine treatment is not recommended
Grade D Action is not recommended
Usefulness/effectiveness is not evident, and indeed the treatment may be harmful
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4. Primary treatment for vaginal cancer
5. Primary vulvar Paget’s disease
10. Nomenclatures and classifications
1. Staging of the disease, FIGO staging and TNM staging
2. WHO histopathological classification (2014)
3. Nomenclature and definition of surgical treatment and 
methods
4. Nomenclature and definition of radiation therapy
Chapter 2: Treatment strategies for vulvar cancer
General consideration
The curative treatment of vulvar cancer requires considera-
tion of both the primary focus of disease in the vulva and the 
inguinal lymph nodes, which are the regional lymph nodes 
of the vulva. In current treatment, surgery is the first choice, 
and historically there has been a transition away from radia-
tion therapy toward surgical procedures in Japan [4, 5]. The 
FIGO classifications of stages also consist of classifications 
of surgical staging, which include detailed histopathologi-
cal findings on lymph node metastasis. However, radiation 
therapy remains a frequently chosen option, as patients with 
vulvar cancer are typically elderly and have a high rate of 
medical complications and high risk for surgery. For cases 
with high-risk factors for postoperative recurrence, post-
operative adjuvant radiation therapy is performed. As with 
uterine cancer, concurrent chemoradiotherapy (CCRT) is 
sometimes tried, and combination chemotherapy may be 
conducted in advanced cases and cases of recurrence (CQ08, 
CQ10).
In recent years, efforts have been paid for individualiza-
tion and reduction of radical treatment with special emphasis 
on the post-treatment quality-of-life (QOL) of the patients. 
However, these demands have sometimes led to confusion 
for the physicians treating vulvar cancer and consistent 
guidelines for determining the treatment plans are needed 
(Fig. 1)
(1) Histopathological approaches
Most epithelial tumors of the vulva are derived from squa-
mous epithelium. These are divided into noninvasive vulvar 
intraepithelial neoplasias (VINs) and squamous cell carcino-
mas. Human papillomavirus (HPV) is detected in approxi-
mately 52–100% of cases of VIN [6]. Formerly, VIN was 
classified into three categories (VIN 1, VIN 2 and VIN 3) 
based on the degree of spread of atypical cells. However, in 
the 2004 classifications of the International Society for the 
Study of Vulvovaginal Disease (ISSVD), VIN was divided 
into ‘usual VIN (uVIN), VIN caused by infection with HPV, 
‘differentiated VIN (dVIN), and VIN not caused by HPV 
infection [7]. In the WHO classification (4th edition) pub-
lished in 2014, VIN related to HPV is called ‘squamous 
intraepithelial lesion’ (SIL). SIL is itself divided into two 
types—low-grade SIL (LSIL), thought to be non-neoplastic 
morphological abnormalities associated with HPV infec-
tion, and high-grade SIL (HSIL), neoplastic lesion which 
carries the risk of carcinogenesis. LSIL corresponds to 
(HPV-related) VIN 1, and HSIL corresponds to VIN 2 and 
3 [8]. Bowenoid papulosis (BP) caused by HPV infection is 
a black pimple or papule that breaks out repeatedly on the 
vulva. Although the histological appearance of BP is identi-
cal to that of uVIN or HSIL, it disappears spontaneously, so 
the term BP is not used in histological diagnosis. All these 
lesions have long attracted attention for their potential to 
undergo malignant change, and the diagnosis and manage-
ment of VIN is a matter of importance (CQ01).
Squamous cell carcinoma is divided into five types—
keratinizing, non-keratinizing, basaloid, warty and verrucous. 
The vulvar squamous cell carcinoma seen in young women is 
frequently caused by infection with HPV and often presents 
in basaloid or warty form. By contrast, vulvar squamous cell 
carcinoma in elderly women is rarely caused by HPV infec-
tion and is usually keratinizing or non-keratinizing [9].
(2) Surgical treatment
Historically, the 5-year survival rate for treatment of vulvar 
cancer improved to 60–70% as a result of the establishment 
of radical vulvectomy and systemic lymphadenectomy (bilat-
eral inguinal lymphadenectomy, pelvic lymphadenectomy) 
in the United Kingdom and the United States [10–12]. Radi-
cal vulvectomy and the continuing series of skin incisions 
leading to bilateral inguinal lymphadenectomy (en bloc type) 
have been vital in enhancing the understanding of dissection 
and other skills necessary for operating on vulvar cancer 
and are basic procedures in the vicissitudes of subsequent 
procedures (CQO2). In recent years, as increased focus has 
been placed on postoperative QOL, efforts have been made 
to improve QOL through the individualization and reduc-
tion of the two components of radical vulvectomy, namely 
surgery on the vulvar disease and surgery on the lymphatic 
nodes [13, 14] (CQ03, CQ05). The results of detailed his-
topathological examinations of metastasis to the inguinal 
lymph nodes and risk factors for prognosis have provided the 
theoretical basis for the reduction and individualization of 
surgical therapies [15–18]. Moreover, the appropriateness of 
reduction has been confirmed in meticulous reviews of sur-
gical therapy in early stage vulvar cancer [19]). In inguinal 
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lymphadenectomy, there have been moves toward reduction 
to superficial inguinal lymphadenectomy alone, but deep 
inguinal lymphadenectomy is still thought to be necessary 
based on the results of a prospective clinical trial and recent 
research on sentinel lymph nodes (SLNs) [19] (CQ05).
In the field of gynecology, the first disease adopting the 
SLN biopsy procedure was vulvar cancer [20] (CQ06). 
There have been several reports of prospective clinical tri-
als and reviews [21–24]. From these results, it has been 
pointed out that omitting the complete removal of the lymph 
nodes when no metastasis is observed in the sentinel nodes 
clearly reduces postoperative complications and prognos-
tic symptoms, thereby contributing to improved postopera-
tive QOL. The problem is that safety must be secured by 
minimizing failure to detect metastasis. Fortunately, it has 
been confirmed that the relapse rate is low when the tar-
get of the surgery is restricted to tumors that are clinically 
metastasis-negative and localized to the vulva. In addition, 
it is emphasized that this procedure must be performed by 
highly trained surgeons and teams [22–24].
The usefulness of extensive surgery resecting surrounding 
affected organs has long been recognized in cases of advanced 
vulvar cancer [25]. In advanced cases of vulvar cancer in 
which the lesion extends from the vagina to the urinary blad-
der or to the anus and/or rectum, anterior, posterior or total 
pelvic exenteration is selected. Because of the wide range of 
defects, various forms of reconstructive surgery must accom-
pany this procedure. Reduced QOL and frequent complica-
tions are problems with this procedure, and in recent years 
reports and reviews have cited the use of preceding radiation 
therapy and chemotherapy as a means of avoiding extensive 
surgery, and these have been reported as useful [26] (CQ04).
When large parts of the vulva and surrounding area are 
lost as a result of vulvar surgery, it is useful to accompany 
with reconstructive surgery. By making proactive use of 
cosmetic reconstructive surgery, it has become possible to 
Fig. 1  Primary treatment for 
vulvar cancer (vulvar tumor and 
inguinal lymph node)
Clinicopathological findings Treatment plan
LSIL Follow up
 (CQ01)
VIN ࣭Local resection
HSIL / dVIN ࣭Laser vaporization࣭Simple vulvectomy
 (CQ01)࣭Wide local excision
Stromal invasion without lymph node resection
Vulvar ≦ 1mm  (CQ03, 05)
biopsy
Tumor diameter ࣭Radical local excision  ***
≦ 2 cm * ipsilateral inguinal node dissection
Lateral lesion  (CQ03, 05, 06)
Stromal invasion
> 1 mm ** ࣭Radical vulvectomy
Central lesion + Bilateral inguinal node dissection
 (CQ03, 05, 06)࣭Radical local excision  ***
* + Bilateral inguinal  node dissection
Lateral lesion ࣭Radical vulvectomy
+ Bilateral inguinal node dissection
 (CQ02, 03, 05, 06)
** ࣭Radical vulvectomy
Resectable Central lesion + Bilateral inguinal node dissection
 (CQ02, 03, 05, 06)
Tumor diameter ࣭Radical vulvectomy
> 2 cm + distal urethral resection, lower vaginectomy 
Locally + Bilateral inguinal node dissection
advanced lesion ࣭Exenteration࣭Radiation therapy
 (preoperative, definitive)࣭Preoperative chemotherapy
 (CQ04, 07, 08)࣭Definitive radiation therapy࣭CCRT
Not resectable Locally ࣭Chemotherapy
advanced lesion ࣭BSC
 (CQ07, 08)
* 1 cm or more lateral from the midline
** Lesions on the midline running through the symphysis and clitoris
*** Isolated lesions without suspected lymph node metastasis
207Int J Clin Oncol (2018) 23:201–234 
1 3
reduce postoperative complications, improve QOL and limit 
impairment of the patient’s appearance. A wide range of 
methods of reconstructive surgery are available, and recon-
struction can be tailored to each excision wound, so careful 
examination is in order before proceeding with surgery [27].
Most patients are elderly and medical complications are 
frequent. Surgeons preparing to proceed with vulvar surgery 
must become experts in postoperative management and man-
agement of the possible complications, particularly excision 
infection and dehiscence of operative wounds.
(3) Radiation therapy
The principal role of radiation therapy is as adjuvant therapy 
to surgery (CQ07). In GOG37, postoperative irradiation of 
the groin and pelvis is reported to be effective if lymph node 
metastasis is clinically recognized, if metastasis to the ingui-
nal lymph nodes is combined with fixation or ulceration, or 
if two or more lymph node metastases are recognized histo-
pathologically [28]. Retrospective research also reports that 
postoperative irradiation is effective against vulvar primary 
lesions in cases with positive or close margins [29].
Because patients with vulvar cancer are typically elderly, 
surgery is not applied in some cases because of medical 
complications. Definitive radiation therapy is applied in 
these cases, as well as in inoperable cases with locally 
advanced cancer (CQ07) [30–32].
Clinical trials have been conducted using preoperative 
irradiation on locally advanced vulvar cancer (CQ07). In 
four phase II trials examining the efficacy of preoperative 
irradiation in cases of stage II−IVa disease and in cases of 
local recurrence, clinical complete remission was observed 
in 27–64% of cases, while histopathological complete remis-
sion was obtained in 31–70% of cases [30, 33–35]. While 
these results indicate the effectiveness of multidisciplinary 
therapy aiming to preserve the function of adjacent organs, 
problems of consistency still remain. The treatment method 
is not uniform and criteria for evaluating operability have not 
been demonstrated. At present, clear evidence is still lack-
ing to support the application of preoperative irradiation to 
locally advanced vulvar cancer as a standard method.
Three-dimensional conformal radiation therapy (3D-
CRT) is a standard method of the external beam radiation 
therapy. However, intensity-modulated radiotherapy (IMRT) 
is a more useful treatment that can deliver a conformal radia-
tion dose to a target extending from the vulva to the inguinal 
region and pelvic lymph nodes.
(4) Chemotherapy
Reports of chemotherapeutic treatment of vulvar cancer have 
increased in recent years. However, all the studies were at 
the phase II trial level, and no standard treatment has been 
established (CQ08, CQ10). Chemotherapy is selected in the 
following situations including preoperative chemotherapy, 
CCRT, postoperative adjuvant chemotherapy, and chemo-
therapy against progression and relapse.
 Clinical questions and recommendations
Surgical treatment
CQ 01: What treatments are recommended for VIN?
Objective
The objective is to determine a treatment method for VIN.
Recommendations
(1) Periodic follow-up is recommended for LSIL (Grade A).
(2) Wide local excision, simple vulvectomy, or laser vapori-
zation may be considered, depending on the case, or laser 
vaporization may be combined with either of the first two 
for HSIL or dVIN (Grade C1).
Comments
Many reports about VIN have been published in accordance 
with the stage categories VIN 1 to VIN 3, advocated in the 
WHO classification 2003 (3rd edition). However, the latest 
WHO classification identifies three new categories as men-
tioned in general consideration. LSIL and HSIL occur in rela-
tively young patients, have been increasing in recent years, 
and represent the majority of VIN cases. Although most cases 
of LSIL regress spontaneously, 6% of HSIL cases have been 
shown to progress to squamous carcinoma [36, 37]. BP, which 
most commonly occurs in patients in their late teens and 20s, 
presents histopathologically as HSIL, but frequently regresses 
spontaneously without any treatment [38–42]. On the other 
hand, dVIN, which is related to lichen sclerosis and lichen 
planus, corresponds to simplex VIN in the old WHO clas-
sification. Simplex VIN often occurs in elderly patients and 
clinically presents as leukoplakia vulvae. It has been pointed 
out that simplex VIN progresses to squamous carcinoma in 
33% of cases, and is more malignant than LSIL or HSIL [37, 
43]. Because LSIL, HSIL and dVIN differ in pathogenesis and 
malignancy, it is preferable that each be managed differently.
Most cases in the old VIN 1 category are LSIL, and 
doubt exists as to their significance as neoplastic lesions. 
However, the old histopathological definition of VIN 1 
includes dVIN which, unlike LSIL, is a neoplastic lesion 
and must be separated from VIN 1 even though the fre-
quency of dVIN occurrence is very low [44]. On that 
understanding, it is preferable to avoid invasive treatment 
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for LSIL and to follow-up periodically. On the other hand, 
HSIL and dVIN are neoplastic lesions which require treat-
ment. In a systematic review of the literature, it was found 
that 9% of untreated cases of VIN 3 progressed to invasive 
carcinomas, and 3% of cases that are surgically excised 
had occult invasive carcinoma [45], indicating that biopsy 
under colposcopy is important to exclude invasion [46]. 
Clinically the evidence for a clear distinction between VIN 
2 and VIN 3 has not been demonstrated, and HSIL, which 
includes both VIN 2 and VIN 3, must be managed with the 
same due consideration [7, 36]. Because HSIL is caused 
by HPV infection, multiple foci of disease can appear in a 
wide-ranging area of the vulva and can also appear, simul-
taneously or allochronically, in and around the uterine cer-
vix, vagina and anus. Careful examination of all of these 
areas is required.
When part of a VIN lesion is suspicious for invasion on the 
appearance of ulceration or irregular surface, it is necessary 
to move proactively to carry out a wide local excision or sim-
ple vulvectomy and conduct a histopathological examination 
on excised specimens, even if biopsy results do not identify 
the invasion. In particular, dVIN is often complicated with, 
or progresses to, invasive carcinoma, and surgical excision 
is the first choice of treatment that should be considered. In 
surgical procedures, physicians should consider the patient’s 
QOL and carry out shallow excision, avoiding deep excision 
of the vulva, and take care in preserving the clitoris [47, 48]. 
If the range of excision is very wide, cosmetic surgery of the 
vulva using skin grafts may be added [7].
If a case of HSIL or dVIN has been comprehensively 
confirmed not to be associated with invasion, it is possible to 
choose laser vaporization instead of surgical excision [49]. If 
the focus of disease is wide, or if there are multiple foci, it is 
possible to treat the condition on a case-by-case basis with 
a combination of vaporization and surgical excision. How-
ever, lesions clinically judged to be BP have been reported to 
regress spontaneously over a period of 3–30 months (median 
period 9.5 months) [39]. If the focus of disease is not seen 
to regress under strict periodic follow-up, treatment should 
be administered.
Recently imiquimod ointment has been used to treat 
LSIL and HSIL to stimulate local immune response [40, 
50–54]. Effectiveness for this approach has been indicated 
by prospective controlled trials and meta-analyses. However, 
no randomized trial has compared imiquimod treatment to 
standard treatment, and the evidence remains insufficient 
due to the small number of cases. Imiquimod treatment is 
not a standard treatment at present and is not listed as an 
insured treatment in Japan.
Currently, a preventive vaccine for HPV is expected 
to show effectiveness against HPV-related lesions, and a 
decline in cases of LSIL and HSIL is anticipated as adop-
tion of the vaccine spreads [55].
Because of the high frequency of recurrence and the pos-
sibility of transition into vulvar cancer, periodic follow-up 
is an important component of management of intraepithelial 
lesions [56].
CQ 02: How should radical vulvectomy be applied? What 
techniques should be used?
Objective
The objective is to examine how radical vulvectomy should 
be applied as a curative excision and the techniques that 
should be used.
Recommendations
(1) Radical vulvectomy is recommended in cases where the 
focus of disease is localized to the vulva or perineum when 
the diameter of the tumor is >2 cm and the stromal invasion 
is >1 mm deep (Grade B).
(2) Resection of vulvar tumors and inguinal lymph nodes 
through separate incisions is recommended (Grade B).
Comments
Until the first half of the 20th century, surgical methods 
for vulvar cancer (squamous carcinoma) were limited to 
vulvectomy in advanced cases. In those days, the 5-year 
survival rate was 20–25%. Later, the survival rate improved 
to >60% with the introduction of en bloc incision, in which 
excision was applied to a continuous mass incorporating 
the skin and subdermal tissue of the vulva and the adipose 
tissue of the groin, including the inguinal lymphatic nodes, 
and combined sometimes with removal of the pelvic lym-
phatic nodes [10, 11]. This combination of radical vulvec-
tomy plus inguinal and pelvic lymphadenectomy became 
the standard surgical procedure. However, many cases were 
accompanied by special site characteristics, very elderly 
patients, or various medical complications. As a result, the 
surgery was associated with significant morbidity, including 
wound dehiscence and infection [57]. In the 1980s, it was 
reported that postoperative complications could be reduced 
through conservative surgery, and the focus began to shift 
toward individualized treatment. However, because of the 
many sites of occurrence and foci of diseases in individuals 
of vulvar cancer and the low frequency of occurrence, many 
reports gathered cases over a period of >20 years. There 
were no randomized controlled trials of incision methods, 
and clear evidence of the effect of conservative surgery on 
vulvar cancer was limited. Complicating matters further 
was the lack of reports based on the new FIGO classifi-
cations; the existing literature was based entirely on the 
1988 FIGO classifications. Therefore, radical vulvectomy 
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should be applied in cases where application of conserva-
tive surgery was not clearly indicated, i.e., the tumor is on 
the median, on the side of the pubic bone, the tumor is on 
both the left and right sides, and multiple foci of disease 
are present.
As an improvement to radical vulvectomy, separate 
incision (or triple incision) was reported in 1962. In this 
approach, the excision of vulvar neoplasia is separated 
from inguinal lymphadenectomy [58]. Later, in the 1980s, a 
method was developed to leave the suprapubic skin intact as 
a skin bridge. The prognosis for this procedure was found to 
be commensurate with historical data in stages I–IV in the 
old (1988) FIGO classifications, and the frequency of wound 
complications decreased dramatically [59–62]. In particular, 
a comparative matched study was conducted on 32 patients 
per group with squamous cell carcinoma localized to the 
vulva and perineum, where the tumor was ≤2 cm in diam-
eter and with lesions >2 cm,in which either en bloc incision 
or separate incision was performed. While overall survival 
and disease-free survival rates were similar for the two 
groups, the dehiscence rate for vulvar and inguinal wounds 
decreased significantly in the case of separate incision [63]. 
Separate incision was shown to be clearly less surgically 
invasive than en bloc incision. Although skin bridge recur-
rence between the vulva and groin was higher for separate 
incision than for en bloc incision, the survival prognosis 
after re-excision was good [64, 65]. Furthermore, cases of 
skin bridge recurrence between the vulva and groin are <1% 
where no gross lymph node metastasis is present. Although 
recurrence in lymph nodes is lower for en bloc incision, no 
difference in survival prognosis is found. Currently, even 
when the frequency of recurrence in lymph nodes and skin 
bridge recurrence between the vulva and groin is considered, 
separate incision is recommended, due to the lesser degree 
of impairment caused by the treatment [66].
When vulvar disease invades the urethral opening or 
lower urethra, it is possible to excise the urethra in a way that 
preserves the urethral sphincter and does not cause inconti-
nence [67]. Invasion to the vagina as far as the lower third 
of the vaginal wall can also be excised at the same time as 
vulvectomy.
The term ‘radical vulvectomy’ also includes the modi-
fied radical vulvectomy which preserves part of the healthy 
vulva.
CQ 03: How should conservative surgery be applied for 
invasive vulvar cancer?
Objective
The objective of this section is to consider methods of con-
servative surgery planned for early stage vulvar cancer and 
how to apply them.
Recommendations
(1) Wide local excision is recommended in cases where the 
diameter of the tumor is ≤2 cm and the stromal invasion is 
≤1 mm deep (Grade B).
(2) Radical local excision can be considered with an excision 
margin of 2 cm in cases where the diameter of the tumor is 
≤2 cm but the stromal invasion is >1 mm deep; or the diam-
eter of the tumor is >2 cm but the lesion is localized laterally 
to the vulva or to the perineum (Grade C1).
Comments
In early stage vulvar cancer, the size of the tumor and 
depth of invasion are related to metastasis to the inguinal 
lymph nodes. If the diameter of the tumor is ≤2 cm and 
the stromal invasion is ≤1 mm deep, wide local excision 
is an appropriate surgical method that offers low surgical 
invasiveness, and inguinal lymphadenectomy can be omit-
ted [68–71].
Radical local excision may be considered in cases where 
the diameter of the tumor is ≤2 cm but the stromal invasion 
is >1 mm deep; or the diameter of the tumor is >2 cm but 
the lesion is secluded (localized laterally to the vulva or to 
the perineum), with surrounding skin tissue normal. This 
surgical technique presents a considerably lower frequency 
of postoperative complications than radical vulvectomy, and 
while the local recurrence rate is reported to be somewhat 
elevated, no difference is observed in the survival period 
[72–75]. The procedure should be limited to tumors which 
occur singly and are lateral (defined as ≥1 cm distant from 
the median line of the lesion).
In this procedure the depth of the excision is similar to that 
of a radical vulvectomy. The excision margin is closely 
related to the probability of local recurrence; if the margin 
is ≤8 mm, the probability of local recurrence is 50%. The 
local control rate is high when the margin is secured for 
8 mm to 1 cm histopathologically [76, 77]. However, even if 
the excision margin is a gross 1 cm, histopathologically the 
excision margin is ≤8 mm after fixation in 50% of cases. To 
ensure sufficient excision margin, a gross distance of 2 cm 
is required [64].
CQ 04: What surgical therapies are recommended for locally 
advanced cases with adjacent organs infiltrated?
Objective
The objective of this section is to examine the usefulness 
of pelvic exenteration in locally advanced cases with deep 
adjacent organ invasion.
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Recommendations
(1) Pelvic exenteration is considered if there is no apparent 
lymph node metastasis and complete excision is anticipated 
(Grade C1).
(2) Preoperative CCRT or chemotherapy is also considered 
in order to avoid QOL decline associated with pelvic exen-
teration (Grade C1).
Comments
In the past, pelvic exenteration was considered as an option 
for locally advanced vulvar cancers deeply infiltrating adja-
cent organs, such as the urethra, urinary bladder, anus and 
rectum. According to a retrospective study on 19 cases of 
vulvar squamous carcinoma receiving pelvic exenteration, 
including 11 cases of primary treatment, the 5-year survival 
rate was 60%. Although no difference was found in overall 
survival between primary treatment and recurrent cases, 
lymph node metastasis was significantly associated with 
overall survival [78]. In a retrospective study of 27 cases of 
stage III−IV vulvar cancer (FIGO 1994) receiving pelvic 
exenteration, including 9 cases of primary treatment, the 
5-year survival rate was 62% [25]. Although no significant 
difference in prognosis was found between primary treat-
ment and recurrent cases, cases with negative lymph node 
metastasis had significantly better prognoses than positive 
cases. Furthermore, cases of pathologically confirmed com-
plete excision had significantly better prognosis than cases of 
pathological incomplete excision. These results indicate that 
the presence/absence of lymph node metastasis and com-
plete excision are the most important prognostic factors [25].
In recent years, conservative surgery preceded by chemo-
therapy or CCRT has been tried as an alternative to pelvic 
exenteration, in order to avoid compromising QOL. Accord-
ing to a retrospective study and Gynecologic Oncology 
Group (GOG) phase II trials, preoperative CCRT can enable 
cases that are unresectable or requiring pelvic exenteration 
to be resectable or to circumvent pelvic exenteration [30, 
34, 79]. However, since no phase III trials exist to date, the 
prognostic impact remains unclear.
CQ 05: How and in what range should lymphadenectomy 
be applied? (Fig. 2)
Objective
Although the superficial inguinal and deep inguinal lymph 
nodes are the regional lymph nodes affected by vulvar can-
cer, efforts have been made to reduce the scope of lymphad-
enectomy according to the disease state. The objective of 
this section is to examine the usefulness and appropriate 
scope of lymphadenectomy.
Recommendations
(1) Inguinal lymphadenectomy can be omitted in cases 
where the tumor is ≤2 cm in diameter and the depth of the 
stromal invasion is ≤1 mm (Grade B).
(2) Inguinal lymphadenectomy includes resection of both 
the superficial and deep inguinal lymph nodes (Grade C1).
(3) Ipsilateral lymphadenectomy alone can be considered 
in cases of a tumor located laterally in which the tumor is 
≤2 cm in diameter (Grade C1).
(4) Postoperative radiation therapy for the groin and pelvis 
is recommended in cases that are positive for metastasis in 
the inguinal lymph nodes, where radical vulvectomy and 
inguinal lymphadenectomy have been conducted (Grade B).
(5) It is recommended at a minimum that the enlarged lymph 
nodes be resected if possible, to conduct a histological exam-
ination for possible metastasis (Grade B).
Comments
Prognosis is extremely poor with recurrence in the inguinal 
lymph nodes in cases of vulvar cancer in which inguinal 
lymphadenectomy was not performed. To ensure elimination 
of lymph node metastasis (the most important factor in prog-
nosis), it is considered essential to conduct inguinofemoral 
lymphadenectomy on at least one side during primary radical 
surgery [80, 81]. In randomized controlled trials (GOG88) 
of radiation therapy to the groin versus lymphadenectomy 
(postoperative irradiation of the diseased-side groin and 
pelvis in cases positive for lymph node metastasis) in cases 
in which metastasis to the inguinal lymph nodes is not sus-
pected, recurrence was higher in the radiation therapy group 
than in the lymphadenectomy group. Both progression-free 
survival time and overall survival time were significantly 
better for the inguinal lymphadenectomy group, prompting 
the researchers to discontinue the trials. These trials suggest 
that lymphadenectomy is more useful than radiation therapy 
to the groin in the treatment of vulvar cancer with no suspi-
cion of inguinal lymph node metastasis [82].
However, in cases where the tumor is ≤2 cm in diameter 
and invasion is ≤1 mm deep (corresponding to clinically 
stage IA), lymph node metastasis occurs in <1% of cases. 
Lymphadenectomy is not recommended in these cases, as 
this treatment is ineffective and in fact harmful [83]. Even 
in cases where invasion is >1 mm, omission of lymphad-
enectomy is reported based on considerations, for example, 
on the presence/absence of lymphovascular space invasion, 
lesion sites and the degree of histological differentiation 
[84]. Further evaluation of criteria for omission of lymphad-
enectomy in these cases is warranted in the future.
Cases have been reported in which no recurrence is con-
firmed when treatment consists of removal of the superfi-
cial inguinal lymph nodes alone, if the tumor is ≤1 cm in 
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diameter and invasion is ≤5 mm deep [68]. Later, retrospec-
tive studies were conducted for cases with early stages that 
were treated with removal of the superficial inguinal lymph 
nodes alone. Recurrence was confirmed on the same side in 
only 4% of cases. This result indicates that treatment con-
sisting solely of superficial inguinal lymphadenectomy is 
effective [74]. However, in a prospective one-arm trial of 
GOG74, superficial inguinal lymphadenectomy alone was 
conducted in cases in which the tumor was ≤2 cm in diam-
eter, no vascular space invasion was present, lymph nodes 
were not swollen and invasion was ≤5 mm deep. In com-
parison with past research results [81, 84], no difference in 
survival rate was found, but the recurrence rate was high 
(16%) and recurrence in the treated lymph nodes side was 
confirmed in six of 121 cases [85]. According to later, ret-
rospective studies, the recurrence rate was also higher for 
superficial inguinal lymphadenectomy alone compared with 
lymphadenectomy as far as the deep inguinal lymph nodes 
[86, 87]. Another study points out that the SLNs are superfi-
cial inguinal lymph nodes in 84% of cases and deep inguinal 
lymph nodes in 16% of cases, indicating that in some cases 
the deep inguinal lymph nodes are the SLNs [88]. These 
findings suggest that lymphadenectomy should be extended 
as far as the deep inguinal lymph nodes.
On the question of whether bilateral inguinal lymphad-
enectomy is necessary, the organs in which bilateral lymph 
flow is observed anatomically consist of the perineum, clit-
oris, and labia minora near the pubis [89]. Retrospective 
studies indicate that when the focus of disease is ≤2 cm in 
diameter and is located on one lateral side, metastasis to 
contralateral lymph nodes occurs in <0.5% of cases [83, 90]. 
These findings suggest that lymphadenectomy can be limited 
to the diseased side in cases where the tumor is ≤2 cm in 
diameter, has not invaded to the midline structures such as 
the clitoris, urethra, vagina, perineal body or anus, is 1–2 cm 
lateral from the median, and no lymph node metastasis is 
Fig. 2  Management of inguinal 
lymph nodes of vulvar cancer
1. Clinically suspected inguinal lymph node metastasis
Clinical findings Treatment plan
of inguinal lymph node
Resection and/or 
Resectable at least histological
examination
 (CQ05)࣭Preoperative or definitive
Not resectable  radiation therapy࣭Preoperative or definitive
CCRT࣭Chemotherapy
 (CQ07,08)
2. Management after inguinal node dissection
Histopathological findings Treatment plan
No metastasis or
one lymph node metastasis Follow up
without extracapsular invasion  (CQ07)
Two or more lymph node Inguinal area and pelvic
metastases or with radiation therapy or 
extracapsular invasion CCRT
 (CQ07,08)
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suspected. However, some reports indicate that bilateral 
lymphadenectomy is necessary if lymph node metastasis has 
occurred on the diseased side [85]. Another study reports 
that metastasis to the non-diseased side is possible only in 
cases where the tumor is ≥2 cm in diameter, invasion is 
≥5 mm deep, and ipsilateral lymph node metastasis is con-
firmed. In these cases, bilateral lymphadenectomy is recom-
mended [91]. On the question of whether bilateral inguinal 
lymphadenectomy is necessary for all medial lesions, some 
reports indicate that metastasis to the opposite side is not 
confirmed in cases where the SLNs are identified on only 
one side [92]. As with the problems of superficial and deep 
inguinal lymphadenectomy, the answer would be changed 
in the future according to the generalization of SLN biopsy.
To examine the question of additional treatment for posi-
tive cases of metastasis to inguinofemoral lymph nodes, ran-
domized controlled trials (GOG37) were conducted compar-
ing pelvic lymphadenectomy with radiation therapy to the 
pelvis and groin after radical vulvectomy and full inguinal 
lymphadenectomy. It was reported that radiation therapy was 
superior in terms of 2-year overall survival rate. The addi-
tion of radiation therapy significantly reduced local recur-
rence and cancer-related death, according to follow-up data 
over a median period of 74 months. As a result, treatment 
with pelvic lymphadenectomy with no radiation therapy was 
not recommended [93]. However, some guidelines indicate 
that all of the swollen inguinal and pelvic lymph nodes may 
be removed and followed by radiation therapy to the groin 
and pelvis in cases where imaging revealed swelling of the 
pelvic lymph nodes. As such, surgery to remove the pelvic 
lymph nodes is by no means repudiated [94].
One retrospective comparative study examined how to 
handle swollen inguinal lymph nodes with suspicion of 
metastasis, comparing removal of the swollen lymph nodes 
alone with systematic lymphadenectomy. It was found that 
the selection of limited surgery had no harmful effect on 
prognosis, provided it was coupled with appropriate postop-
erative irradiation [95]. Although the study did not draw any 
conclusions regarding the necessity of systematic lymphad-
enectomy, it seems likely that at least the excision of swollen 
lymph nodes suspected of metastasis should be considered, 
and the presence/absence of metastasis examined histologi-
cally, before considering radiation therapy.
CQ 06: Can SLN biopsy be used to avoid performing a 
lymphadenectomy?
Objective
The objective of this section is to examine whether systemic 
inguinal lymphadenectomy can be avoided by using SLN 
biopsy.
Recommendations
SLN biopsy may be performed as a means to avoid an 
inguinal lymphadenectomy in cases in which metastasis 
to the inguinal lymph nodes is not suspected clinically. In 
view of the current status of experience in the procedure in 
Japan, this action should be considered as an experimental 
approach (Grade C1).
Comments
The identification of SLNs for vulvar cancer is one of the 
most progressed areas of inquiry in gynecology [96, 97]. In 
principle, SLN biopsies are used in cases with vulvar cancer 
localized to the vulva and perineum with no suspicion of 
lymph node metastasis.
According to numerous reports from individual institu-
tions, there are three methods of identifying the SLNs—the 
dye method alone, the radioisotope (RI) method alone, and 
the dye/RI combined method [98, 99]. Isosulfan blue and 
patent blue are used in the dye method, and technetium-99 m 
is used in the RI method. Recently, a feasibility study has 
been reported of a fluorescence method using indocyanin 
green dye in cases of vulvar cancer [100]. An analysis of 
the combined method based on 26 journal articles and 1271 
cases indicates that this method provides an 86% identifi-
cation rate and a false negative rate of 5.8%. For the RI 
method, analysis of seven articles and 116 cases yields an 
identification rate of 83% and a false-negative rate of 8.8%. 
For the dye method alone, analysis of three articles and 111 
cases provides a low identification rate of 64% and a false-
negative rate of 8.7%. Most reports recommend use of the 
combined method [98].
According to a meta-analysis, the following factors affect 
the identification rate for SLNs and the sensitivity for metas-
tasis—method of identification of SLNs, and localization of 
the focus of disease in the vulva, i.e., whether the focus of 
disease is located medially or laterally. An increase in false 
negatives for medial lesions has been reported [99]. A multi-
institutional validation study similarly report false negatives 
for medial lesions [21]. Similarly, one meta-analysis indi-
cated a decrease in identification rate for SLNs in cases with 
palpable swollen lymph nodes or with large tumors [99].
In a multi-institutional prospective study, SLN biopsies 
were used to avoid systemic lymphadenectomy when the 
SLNs were negative for metastasis. In the trial, 403 cases of 
tumors <4 cm in diameter and localized in the vulva were 
examined. The recurrence rate in the inguinal lymph nodes 
was 3%, indicating the effectiveness of the SLN biopsy. In 
particular, the recurrence rate was 2.3% in isolated vulvar dis-
ease [22]. Complications of SLN biopsies such as wound trou-
ble, cellulitis and lymphedema were rare in the study [101].
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In a cost-effectiveness analysis, omission of lymphad-
enectomy based on SLN biopsy was compared with systemic 
inguinal lymphadenectomy. This report found that the most 
cost-effective approach was to identify SLNs using the com-
bined method (dye plus RI) and perform ultrastaging using 
immunostaining to search for metastasis [102]. In the multi-
institutional trials cited above, the metastasis detection rate 
was found to increase gradually when immunostaining was 
combined with multi-section searches (ultrastaging) using 
ordinary hemotoxylin-eosin (H&E) dye [22]. However, the 
intervals in which sections were prepared and the number of 
sections searched were not consistent in the reports.
Frozen section diagnosis during surgery is reported as 
useful, with a sensitivity of 89% and a negative predictive 
value of 93% [103]. However, the sensitivity and negative 
predictive value were both low at 48 and 78%, respectively, 
in a multi-institutional trial [22]. Opinion differs as to 
whether this practice should be combined with postopera-
tive ultrastaging or omitted when searching for metastasis 
in SLNs.
Even though evidence was accumulated for the usefulness 
of SLN biopsy in vulvar cancer, no results of randomized 
controlled trials currently exist comparing this approach 
with standard treatments. In Japan, almost no results are 
available on vulvar cancer, as health insurance covers SLN 
biopsies only for breast cancer and malignant melanomas. 
Under these conditions, the first step should be to conduct 
clinical trials on the omission of lymphadenectomy on the 
basis of SLN biopsies. It is also preferable that the omis-
sion of systematic lymphadenectomy be carried out not by 
gynecologists alone but with the cooperation of physicians 
in other medical fields who are thoroughly trained in SLN 
biopsies, as well as radiologists, pathologists and others.
Radiation therapy for vulvar cancer
CQ 07: How should radiation therapy be applied and what 
methods should be used?
Objective
Radiation therapy is conducted as an adjuvant treatment to 
surgery and as a definitive treatment. The objective is to 
examine how radiation therapy should be applied and the 
methods that should be used.
Recommendations
(1) Postoperative irradiation of the primary site may be 
considered if the excision margin is <8 mm, or advanced 
vascular space invasion is confirmed (Grade C1).
(2) Postoperative irradiation of the groin and pelvis is recom-
mended, if two or more metastases or extracapsular invasion 
of lymph node metastasis is confirmed in the inguinal lymph 
nodes (Grade B).
(3) Omission of postoperative irradiation may be considered, 
when one metastasis alone of the inguinal lymph nodes has 
occurred without extracapsular invasion (Grade C1).
(4) Definitive radiation therapy may be considered in inoper-
able cases (Grade C1).
(5) Preoperative irradiation may be considered as a means 
of preserving the function of adjacent organs in locally 
advanced cases (Grade C1).
(6) Concurrent chemotherapy with a single platinum-based drug 
or combination of this drug may be considered (Grade C1).
Comments
Postoperative recurrence of vulvar cancer is associated with 
the degree of tumor invasion and lymph node metastasis 
[76, 81, 104]. Because the risk of local recurrence appears 
if excision margins are <8 mm [76], postoperative adjuvant 
treatment for the primary site is required. In a retrospective 
study, postoperative irradiation of the primary site is reported 
to be effective in cases with close margins or where advanced 
vascular invasion is recognized [29]. As mentioned in CQ05, 
randomized controlled trials (GOG37) have demonstrated the 
superiority of postoperative irradiation to pelvic lymph node 
dissection when inguinal lymph node metastasis is recog-
nized, when lymph node metastasis has occurred in combina-
tion with fixation or ulceration, or when two or more lymph 
node metastases are confirmed histopathologically [28, 93]. 
One retrospective study of 208 cases of single lymph node 
metastasis found that postoperative irradiation was effective 
in increasing disease-specific survival rate. Unfortunately, 
this study is problematic as it fails to consider extracapsular 
invasion in lymph node metastasis, which is a major risk fac-
tor for recurrence [105]. Later, a multi-institutional retrospec-
tive study was conducted on 75 cases of single lymph node 
metastasis without extracapsular invasion. This study did not 
confirm that postoperative irradiation was beneficial [106]. 
Based on these findings, inguinal and pelvic postoperative 
irradiation is recommended when two or more metastases are 
confirmed in the inguinal lymph nodes, or extracapsular inva-
sion is confirmed. In practice, the field of pelvic lymph nodes 
covers the internal and external iliac lymph nodes and the 
obturator lymph nodes, and the radiation dose is 45–50.4 Gy 
in 25–28 fractions.
Definitive radiation therapy is considered in cases where 
surgery is not applicable, such as in elderly patients or in the 
case of medical complications, and in cases that are judged 
inoperable, such as those with advanced local progression or 
metastasis in inguinal lymph nodes that cannot be removed. 
When planning radiation therapy, the groin is included in the 
clinical target volume (CTV) even if no metastasis is clini-
cally confirmed, and the CTV is extended to the pelvic lymph 
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nodes if metastasis is clinically confirmed in the inguinal 
lymph nodes. After external beam irradiation of 45–50 Gy 
of a CTV encompassing the lymph node area, the irradiation 
field is shrunk to the focus of disease and the dose is increased 
to 60–70 Gy. Because it is necessary to apply a uniform dose 
to a complex CTV that includes the vulva, groin and pelvic 
lymph nodes, 3D-CRT combining X-ray and electron beam 
irradiation is applied. Compared with conventional 3D-CRT, 
IMRT enables more conformal dose distribution to the target 
and reduced dose on surrounding normal organs [32].
Some reports have examined the usefulness of multidisci-
plinary therapy using preoperative irradiation on tumors that 
are inoperable due to invasion of adjacent organs, or in cases 
of locally advanced vulvar cancer requiring exenterative sur-
gery. In the results of four phase II trials targeting stages 
II, III, IVA and cases in local recurrence, clinical complete 
remission was confirmed in 27–64% of cases, 72–97% of 
cases became operable, and histopathological complete 
remission was obtained in 31–70% of surgical cases [30, 
33–35]. Although the scale of the trials was small (41–71 
cases), the results of each trial indicated the effectiveness 
of multidisciplinary therapy aimed at preserving the func-
tion of adjacent organs. However, the criteria for application 
of surgery remain unclear; QOL evaluation is not always 
performed, and the degree to which histopathological com-
plete remission improves prognosis is not clearly understood 
[107]. Furthermore, no phase III trials have been conducted 
indicating the effectiveness of preoperative irradiation on 
advanced local vulvar cancer [26]. Accordingly, physicians 
must exercise careful judgment before applying preoperative 
irradiation, even with the aim of preserving organ function.
Many recent reports indicate the concurrent use of cispl-
atin (40 mg/m2/week), and adverse events were found to be 
within the acceptable range [30–32]. If the patient’s general 
condition and organ function meet certain criteria, the use 
of concurrent chemotherapy based on platinum-based drugs 
may be considered.
The most common acute radiation morbidity is radiation 
dermatitis, which occurs in virtually all cases. In some cases 
this condition becomes serious or is combined with infec-
tion, requiring the suspension or termination of treatment 
[108]. Careful management is required, giving due consid-
eration to protection of the skin and prevention of infection 
during radiation therapy.
Chemotherapy for the vulvar cancer
CQ 08: How should chemotherapy be applied?
Objective
The purpose of this section is to examine the usefulness of 
chemotherapy as a treatment for vulvar cancer.
Recommendations
(1) Preoperative chemotherapy may be considered for locally 
advanced cases (Grade C1).
(2) Systemic chemotherapy may be considered for cases of 
progression or recurrence of distant metastasis (Grade C1).
Comments
In contrast to the effectiveness of radiation therapy in the 
treatment of advanced vulvar cancer, there are few reports 
for chemotherapy which has been regarded as ineffective. 
Even so, attempts have been made to use chemotherapy 
as a preoperative adjuvant treatment for advanced cases to 
make them operable. Chemotherapy is also expected to be 
beneficial in advanced cases with distant metastasis and in 
recurrent cases.
Primary surgery of locally advanced vulvar cancer 
requires pelvic exenteration or other extended surgical meth-
ods. These surgeries result in impaired QOL. To address this 
problem, efforts have been made to use preoperative chemo-
therapy in advanced cases of vulvar cancer to avoid extended 
surgery. Many reports on these attempts have been generated 
from European organizations such as the European Organi-
zation for Research and Treatment of Cancer (EORTC). In 
these trials, preoperative chemotherapy was tested on locally 
advanced vulvar cancer using drugs such as bleomycin, meth-
otrexate, lomustine, cisplatin, 5-fluorouracil, paclitaxel and 
vincristine. The reported response rate and surgical comple-
tion rate after chemotherapy were both favorable at approxi-
mately 60% and 57–90%, respectively [109–113]. In each 
report, however, the number of cases examined was small, 
and no standard treatment regimen was established. Problems 
remain with respect to the selection of drugs.
In phase II trials, the response rate of preoperative chemo-
therapy was higher than that of chemotherapy usually applied 
to advanced and recurrent cases. In most cases of recurrence, 
the patient has undergone radiation therapy in the past, and 
the low response rate may be found in advanced and recur-
rent cases for chemotherapy. The reported response rate for 
treatment with cisplatin alone [114], mitoxantrone [115] and a 
weekly dose of paclitaxel plus carboplatin [116] is 0% in each 
case, while for paclitaxel alone the response rate is 14% [117]. 
In more encouraging treatment results, the response rate for 
bleomycin alone or concurrent with mitomycin, reported in 
1980, was 50% [118], while a response rate of 40% is reported 
for concurrent treatment with cisplatin and vinorelbine [119]. 
Because no studies have found reproducibly high response 
rates of chemotherapy, no treatments could be regarded as 
the standard treatment. However, in advanced cases with dis-
tant metastasis and in recurrent cases after radiation therapy, 
chemotherapy may be the only treatment option. Trials are 
currently under way using a wide variety of drugs [120].
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Although the most widely used postoperative adjuvant 
treatment for vulvar cancer is radiation therapy, the use of 
chemotherapy as a postoperative adjuvant treatment is also 
reported [121]. In this report, cisplatin was used postopera-
tively as adjuvant treatment in 14 cases of vulvar cancer with 
lymph node metastasis, and the recurrence rate was low. 
However, no other reports of similar results exist, and post-
operative adjuvant chemotherapy has not become a standard 
treatment for vulvar cancer.
Follow-up and treatment for recurrent diseases
CQ 09: How should periodic follow-up be conducted after 
treatment?
Objective
The purpose is to examine the intervals and methods by 
which appropriate periodic follow-up should be conducted 
regarding recurrence and complications associated with 
treatment.
Recommendations
(1) A rough guide for the intervals in periodic follow-up 
after treatment is as follows (Grade C1):
First and second years: every one to three months
Third to fifth years: every six months
Sixth and subsequent years: once a year
(2) Conduct medical interviews, inspection, palpation, 
cytology, biopsy, chest X-ray, tumor markers and computed 
tomography (CT). Monitor not only for recurrence but also 
for complications (Grade C1).
Comments
The purpose of periodic follow-up is to detect recurrence 
as soon as possible, improve the prognosis, and to mitigate 
and reduce the loss of QOL caused by treatment. However, 
no evidence exists that diagnosis of recurrence through peri-
odic follow-up after treatment leads to improved prognosis 
in vulvar cancer. Moreover, no reliable research has been 
performed regarding the interval of periodic follow-up and 
items examined during periodic follow-up after treatment of 
vulvar cancer, and no consensus can be obtained.
Guidelines in countries other than Japan were reviewed. In 
the United Kingdom, the Royal College of Obstetricians and 
Gynecologists recommends observation every 3 months during 
the first year after treatment, every 6 months in the second and 
third years, and once every 12 months in the fourth and sub-
sequent years [122]. In contrast, the National Cancer Institute 
(NCI) of the United States has no recommendations regarding 
periodic follow-up [123]. The recommendations are based on 
the results of retrospective studies indicating that local recur-
rences diagnosed at a routinely scheduled follow-up were found 
to have a smaller greater dimension compared with recurrences 
detected by chance [124]. However, no significant effect on sur-
vival rate was confirmed. In retrospective studies examining the 
timing, site of recurrence and the prognosis, 55–67% of recur-
rences occurred within 2 years after the first surgery [125, 126]. 
The most important predictive factors for recurrence are stage 
and metastasis to the inguinal nodes [125–127]. In cases that 
are positive for metastasis to the inguinal nodes at the time of 
initial treatment, recurrence within the first 2 years is common. 
On the other hand, in cases that are negative for metastasis to the 
inguinal nodes at the time of initial treatment, the recurrence rate 
is low, and recurrence sites are mainly local [125].
Because the common sites of recurrence are the local site 
and the inguinal nodes, inspection and palpation of these sites 
are most important. If recurrence is suspected, cytology and 
biopsy should be conducted. Other useful examination items 
are chest X-ray, tumor markers, CT, magnetic resonance 
imaging (MRI) and 2-deoxy-2-[18F]fluoro-d-deoxy glucose-
positron emission tomography (FDG-PET). No set criteria 
are established regarding timing or other aspects of these 
tests. Detailed medical interviews of the patient’s condition 
enable the physician to make decisions after considering the 
risk of recurrence in each case. Although recurrence within 
the first 2 years is common, recurrence also occurs ≥5 years 
after initial treatment, which demonstrates the need for long-
term follow-up [127].
The probability of postoperative complications in vulvar 
cancer is relatively high [128]. The rate of wound compli-
cations of the vulva ranges from 9−58%, while frequent 
urination or urinary incontinence is confirmed in 8–28% 
of cases. The frequency of inguinal complications follow-
ing inguinal lymphadenectomy is reported as 21–39% for 
infection, 17–39% for wound dehiscence, 21–57% for cellu-
litis, 11–40% for lymphocele and 14–48% for lymphedema. 
Most cases of lymphedema occur in the legs within the first 
12 months after surgery and are chronic. Lymphedema is 
aggravated by obesity, infection, addition of radiation therapy 
and deep vein thrombosis after surgery. Furthermore, psycho-
logical and social problems frequently occur after surgery 
for vulvar cancer, including psychological stress, pain during 
sexual intercourse, decreased libido, frequent urination and 
incontinence. Because these problems are detrimental to a 
patient’s QOL, long-term periodic follow-up is necessary.
CQ 10: What treatments are recommended for recurrent 
disease? (Fig. 3)
Objective
The objective of this section is to examine the most useful 
treatment approaches for recurrence.
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Recommendations
(1) Re-excision is considered for postoperative localized 
recurrence (Grade C1).
(2) CCRT is considered for local recurrence unresectable 
or infiltrating adjacent organs, if unirradiated (Grade C1).
(3) Systemic chemotherapy is considered for recurrences in 
the pelvis, with distant metastasis or with multiple lesions 
(Grade C1).
(4) Best supportive care (BSC) is considered if no other 
effective treatments are left (Grade C1).
Comments
When deciding treatment for recurrence, the site of recur-
rence, details of previous treatments and performance status 
must be taken into account [129]. A retrospective study on 
502 cases of vulvar squamous carcinoma in 5 institutions in 
Italy reported that recurrence occurred in 37% and the 5-year 
survival rate varied by recurrence site—60% for the vulva, 
27% for the groin and pelvis, 15% for distant metastasis, and 
14% for multiple lesions [127].
For localized recurrence, re-excision is considered. In 
a retrospective multi-institutional study of 102 recurrent 
cases receiving re-excision following radical vulvectomy, the 
disease-free survival rate was 56% and the 5-year survival 
rate was 61%. Cases with inguinal lymph node metastasis 
at recurrence showed significantly poor prognosis [130]. 
If lymphadenectomy has never been performed, unilateral 
or bilateral inguinal lymphadenectomy may be performed, 
depending on the site of recurrence. If the re-excision mar-
gin or lymph node metastasis turns out positive, CCRT may 
be added if radiotherapy has not yet been performed [129].
For local recurrence to unresectable or infiltrating adja-
cent organs, CCRT is considered if unirradiated. According 
to a retrospective study where CCRT was performed for 7 
unirradiated cases of postoperative local recurrence of vulvar 
squamous carcinoma which were unresectable or required 
pelvic exenteration, 4 yielded complete response (CR), 3 
yielded partial response (PR), and the 2-year survival rate 
Fig. 3  Treatment of vulvar 
cancer. Treatment of distant 
metastasis, recurrent tumor
Clinicopathological findings Treatment plan࣭Chemotherapy
Distant metastasis ࣭Palliative radiation therapy࣭BSC
 (CQ07,08)
Resectable ࣭Local resection࣭Radiation therapy
Local recurrence  (CQ10)
No previous ࣭Preoperative or primary
radiation therapy  radiation therapy
Not resectable ࣭Preoperative or primaryࠉCCRT࣭Preoperative chemotherapy࣭Palliative radiation therapy࣭BSC
 (CQ07,08)
Previous ࣭Chemotherapy
radiation therapy ࣭BSC
No previous ࣭Inguinal LND
lymph node + Radiation therapy
dissection ࣭Inguinal LND
+ CCRT
Inguinal recurrence  (CQ05,10)
No previous ࣭Radiation therapy
radiation therapy ࣭CCRT
Previous  (CQ0㸵,10)
lymph node
dissection Previous ࣭Chemotherapy
radiation therapy ࣭BSC
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was 28% [79]. In another study on 15 unirradiated cases 
of postoperative recurrence which received CCRT, 8 cases 
yielded CR, and the 2-year survival rate was 46% [131].
Prospective trials also confirm that the prognosis for 
inguinal recurrence is extremely poor. According to an anal-
ysis of two prospective trials (GOG74, GOG88), recurrence 
occurred in 37 out of 143 cases of initial treatment of vulvar 
squamous carcinoma. Significantly poor prognosis was dem-
onstrated in 12 cases of inguinal recurrence with a median 
survival of 9.4 months compared to 20 cases of vulvar recur-
rence with a median survival of 52.4 months [132]. In cases 
of inguinal recurrence which have not received lymphad-
enectomy or radiotherapy, bilateral inguinal lymphadenec-
tomy followed by radiotherapy or CCRT is considered. In 
cases after external irradiation, interstitial irradiation may be 
considered, but complications are frequent [129]. Re-exci-
sion for inguinal recurrence after irradiation also requires 
caution because of frequent postoperative complications.
In cases of recurrence in the pelvis, with distant metas-
tasis or with multiple lesions, chemotherapy is considered. 
Several phase II studies reported on the effects of chemo-
therapy for recurrent diseases [109, 117, 119]. However, no 
treatment could be regarded as the standard treatment as 
previously mentioned in CQ08. Chemotherapy is considered 
only when no other effective treatments are available.
In recurrent vulvar cancer, most patients are advanced 
in age and not many efficacious treatments are available. 
Therefore, early introduction of BSC including palliative 
radiotherapy is considered for the purpose of symptomatic 
relief and QOL improvement [133].
Chapter 3: Treatment strategies for vaginal cancer
 General consideration
Patients suffering from vaginal cancer are elderly, and selected 
therapy is usually radiation therapy and CCRT, as is the practice 
with cervical cancer. The most common sites for vaginal cancer 
are the upper third of the vagina (56%), followed by the lower 
third (31%) and the middle third (13%) [134]. It is believed that 
the lymphatic routes of tumors localized in the upper two-thirds 
of the vagina drain mainly into the pelvic lymph nodes, while 
those in the lower third of the vagina drain into the inguinal 
lymph nodes. Therefore, the routes of metastasis vary according 
to the site and range of the primary tumor. Planning the treat-
ment for vaginal lesions and for regional lymph nodes requires 
in consideration of the way of spread [135].
The type of surgical therapy is also chosen based on the 
site and range of occurrence of the primary lesion. At this 
time the physician must consider both removal of the pri-
mary lesion and regional lymph nodes simultaneously.
Vaginal cancer is sometimes treated with chemotherapy 
in advanced or relapse cases, but evidence of its efficacy is 
scarce due to the small number of cases. Currently, it is used 
in conformity with the practice for cervical cancer (Fig. 4)
(1) Histopathological approaches
Most cancers originating in the vagina are squamous cell 
carcinomas. Histologically these can be divided into five 
types—keratinizing, non-keratinizing, basaloid, verrucous 
and warty. HPV is detected in about 80% of cases of vagi-
nal squamous cell carcinoma, and HPV is most frequently 
detected in the non-keratinizing, basaloid and warty forms, 
in that order [136].
Vaginal intraepithelial neoplasia (VAIN) is a proliferation 
of atypical squamous cells within the vaginal epithelium but 
is not accompanied by interstitial infiltrate. As with cervi-
cal intraepithelial neoplasia (CIN), it is classified into three 
grades (VAIN 1, VAIN 2, VAIN 3) according to the level of 
atypical cell proliferation. Most cases of VAIN are caused 
by HPV infection [137]. In recent years, as with VIN, VAINs 
caused by HPV are classified into LSIL and HSIL [138, 
139]. In these classifications, LSIL corresponds to VAIN 1 
and HSIL corresponds to VAIN 2 and 3. The potential for 
malignancy is less clear for VAIN than for CIN and VIN 
(CQ11).
Although primary adenocarcinoma of the vagina is rare, 
clear-cell carcinoma in the women who are exposed to syn-
thetic non-steroid estrogens such as diethylstilbestrol (DES) 
in utero has been reported [140]. Even among women never 
exposed to DES, the most common form of adenocarcinoma 
occurring in the vagina is clear-cell adenocarcinoma. Devel-
opmental abnormalities of the urogenital system, vaginal 
adenosis, and endometriosis are possible origins of the vagi-
nal adenocarcinoma.
(2) Radiation therapy
Radiation therapy is a generally used treatment for vaginal 
cancer to preserve the function of adjacent organs (CQ12). 
However, because of the rarity of these tumors, no ran-
domized controlled trials exist, and only retrospective 
studies in single facilities are reported. According to these 
reports, the significant prognostic factors are clinical stage 
and tumor size [141–151], and the main recurrence pattern 
is local recurrence [141, 143]. The 5-year pelvic control 
rate for radiation therapy is 80–90% in stage I, 50–70% in 
stage II, 50–60% in stage III and 30% in stage IV [141–143, 
152]. The 5-year disease-specific survival rate is 80–90% 
in stage I, 70–80% in stage II, 50–60% in stage III and 
10–20% in stage IV [142–144, 148], and the 5-year over-
all survival rate is 70–80% in stage I, 50–70% in stage II, 
30–50% in stage III and 0–20% in stage IV [144, 149]. The 
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5-year rate of severe radiation morbidity is reported to be 
approximately 5–20% including ulceration of the vaginal 
mucosa and vulva, vaginal stenosis, rectal stenosis, rec-
tovaginal fistula and fistula of the urinary bladder [141, 
143–146, 148].
Methods of radiation therapy have recently changed in 
many ways. Brachytherapy has changed from low-dose-rate to 
high-dose-rate irradiation. Recently, with the growing adop-
tion of image-guided brachytherapy (IMBT), it has become 
possible to evaluate doses accurately based on 3D treatment 
planning using CT or MRI [150, 151]. In external beam 
irradiation, 3D-CRT has become standard, and increasing 
numbers of facilities are using IMRT, improving dose dis-
tribution [152].
(3) Surgical therapy
In principle, the mainstay therapy for vaginal cancer is radia-
tion therapy. However, surgical therapy is also an option, 
depending on the location and range of the focus/foci of 
disease (CQ13). In particular, in the case of vaginal cancer 
occurring in the upper third of the vagina, surgical therapy 
consisting of hysterectomy extended to the vagina is a good 
option [153]. If vaginal cancer is accompanied by widespread 
Fig. 4  Primary treatment for 
vaginal cancer
Clinical stage Clinicopathological Treatment plan
findings
LSIL Follow up
 (CQ11)
VAIN ࣭Resection
HSIL ࣭Laser vaporization
 (CQ11)࣭Brachytherapy
Tumor thickness ࣭External-beam radiation therapy + Brachytherapy
≦ 5mm ࣭Surgery
 (CQ12,13)
Stage I ࣭External-beam radiation therapy + Brachytherapy࣭External-beam radiation therapy
Tumor thickness ࣭Surgery
 > 5mm  (CQ12,13)࣭External-beam radiation therapy + Brachytherapy
Stage II ࣭External-beam radiation therapy࣭Surgery
 (CQ12,13)࣭External-beam radiation therapy + Brachytherapy
Stage III ࣭External-beam radiation therapy࣭CCRT
 (CQ12)࣭External-beam radiation therapy + Brachytherapy࣭External-beam radiation therapy
Stage IV A ࣭CCRT࣭Exenteration
Stage IV  (CQ12,13)
Stage IV B ࣭Chemotherapy࣭BSC
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intraepithelial neoplasia in the vagina, a total vaginectomy 
may sometimes be selected. Moreover, in carefully selected 
cases of locally advanced vaginal cancer with no metastasis, 
pelvic exenteration is sometimes performed [154].
 Clinical questions and recommendations
Treatment for VAIN
CQ 11: What are the recommended treatments for VAIN?
Objective
The objective is to examine therapies for treating VAIN.
Recommendations
(1) Conduct periodic follow-up for LSIL (Grade A).
(2) Surgical therapies may include local, partial or total 
vaginectomy, depending on the case for HSIL. Laser vapor-
ization may be considered for more conservative therapy 
(Grade C1).
(3) Loop electrosurgical excision procedure (LEEP) is not 
recommended due to the risk of injury to the urinary bladder 
or rectum (Grade D).
Comments
Many reports concerning VAIN have been published in 
accordance with the categories VAIN 1 to VAIN 3, advo-
cated in the WHO classification of 2003 (3rd edition). The 
frequency of occurrence of VAIN is low, approximately 
1% of that of CIN, which is also caused by HPV infection 
[155]. Many VAIN cases are combined with VIN and CIN 
as part of the effects of HPV infection [156, 157]. VAIN is 
often seen in patients whose immune systems are compro-
mised, whether from an immunodeficiency disease such as 
human immunodeficiency virus (HIV) or long-term use of 
immunosuppressants or steroids in connection with a trans-
plant procedure [158]. In addition, VAIN cases are often 
associated with a past hysterectomy due to CIN or cervical 
cancer, or a history of radiation therapy [155, 159–162]. 
Like VIN, VAIN can present with multiple foci of disease, 
or with a focus of disease spread over a wide area. Before 
initiating treatment, the entire vagina must be examined 
thoroughly.
In a retrospective examination of therapeutic interven-
tion in cases of VAIN, treatment was provided in 30% of 
cases of VAIN 1, 77% of VAIN 2 and 93% of VAIN 3 
[163]. In LSIL, which corresponds to VAIN 1, spontane-
ous regression of disease occurs in roughly half of all cases 
with periodic follow-up alone. Accordingly, proactive 
treatment is often reserved for HSIL, which corresponds 
to VAIN 2 and VAIN3 [157, 159]. As reports indicate that 
latent cancers are hidden in 12–13% of HSIL cases [160, 
164], surgical excision may be considered in cases with 
suspicion of invasive carcinoma. Because >80% of VAIN 
cases occur in the upper third of the vagina [160, 164], 
treatment with partial vaginectomy is often reported [159, 
164]. Depending on the range and sites of the foci of dis-
ease, local excision or total vaginectomy may be performed 
[160, 162, 165]. A variety of excision approaches are also 
adopted, including transvaginal, laparotomic and laparo-
scopic surgery, and these may or may not be accompanied 
by hysterectomy [162, 166]. Because of the anatomical 
structure of the vagina, complications such as damage to 
the urinary bladder and rectum and fistulation have been 
reported after surgical excision [165, 167]. Moreover, 
VAIN patients sometimes have a history of hysterectomy 
or radiation therapy; these conditions can render surgical 
excision difficult. Physicians must consider individually 
when selecting a treatment method.
When invasive carcinoma can be ruled out after sufficient 
examination, the most widely used preservative treatment 
is laser vaporization [167–170]. Unfortunately, recurrence 
rates are high in these cases, requiring repeated treatment 
or surgical excision, and continuous observation [162, 163]. 
The use of LEEP is reported [171], but is not recommended 
due to the high risk of damage to the urinary bladder and 
rectum [172]. In cases that are resistant to treatment, intra-
cavitary irradiation [173, 174] and local administration of 
5-fluorouracil [175] have been reported. As with surgical 
excision, the risk of impairment of the urinary bladder and 
rectum is considerable.
Cases of VAIN are few and are often accompanied by 
primary illnesses that compromise immunity, combined 
with VIN or CIN, or are associated with a history of hyster-
ectomy or radiation therapy. These circumstances render it 
difficult to establish clinical trials to gather evidence, such 
as randomized controlled trials. Cases of VAIN need to be 
managed on an individual basis, accompanied by long-term 
periodic follow-up.
Radiation therapy for the vaginal cancer
CQ 12: How should radiation therapy be applied, and what 
methods should be used?
Objective
The objective is to examine how to apply radiation therapy 
to vaginal cancer and the methods of radiation therapy to 
use.
220 Int J Clin Oncol (2018) 23:201–234
1 3
Recommendations
(1) Brachytherapy may be performed alone or in combina-
tion with external beam irradiation for stage I vaginal cancer 
with tumor thickness of ≤5 mm (Grade C1).
(2) External beam irradiation may be performed in combina-
tion with brachytherapy or alone for stage I vaginal cancer 
with tumor thickness >5 mm, or for vaginal cancer in stages 
II to IVA (Grade C1).
(3) Concurrent chemotherapy with a single platinum-based drug 
or combination of this drug may be considered (Grade C1).
Comments
Radiation therapy to treat vaginal cancer may consist of 
brachytherapy, external beam irradiation, or a combina-
tion of the two, depending on the condition of the focus of 
disease.
The JASTRO guidelines state that brachytherapy can be 
applied as intracavitary irradiation alone in cases of stage 
I vaginal cancer in which the tumor is ≤5 mm thick [151, 
176]. However, the intra-pelvic recurrence rate of patients 
treated with intracavitary irradiation alone for stage I vaginal 
cancer was 20–33% [143, 146]. Physicians must take care 
regarding underestimation of invasion of the submucosa. If 
there is suspicion of invasion to the submucosa, intracavitary 
irradiation must be combined with external beam irradiation 
regardless of the size of the tumor even for stage I vaginal 
cancer. External beam irradiation is performed in combina-
tion with brachytherapy or alone for vaginal cancers >5 mm 
in thickness, or for vaginal cancer in stages II to IVA.
The external beam irradiation is applied first. If the pri-
mary lesion is in the upper two-thirds of the vagina, the 
CTV includes the area of the obturator lymph nodes, inter-
nal and external iliac lymph nodes, common iliac lymph 
nodes and presacral lymph nodes. If the primary lesion is 
in the lower third of the vagina, the CTV covers the groin 
[141, 143]. The CTV must include the area of the rectal 
lymphatic nodes if the tumor invades the posterior wall 
of the vagina, and must include the vulva if it invades the 
vaginal entrance. Irradiation with central shielding should 
begin at 30–40 Gy and rise to 45–50 Gy [143]. After cen-
tral shielding, additional doses are added via brachytherapy 
to the primary lesion. When the dose reaches 30–40 Gy, 
the additional dose is administered by brachytherapy if the 
boundaries of the residual tumor are clear, invasion around 
the vagina is ≤50–60%, and no deep invasion of the para-
colpium is observed [3]. A cylindrical or ovoid applicator 
may be used to conduct intracavitary irradiation if the focus 
of disease is localized in the vaginal fornix, or if the tumor 
is ≤5 mm thick. According to the consensus guidelines of 
the American Brachytherapy Society (ABS) on interstitial 
irradiation of vaginal cancer, however, interstitial irradiation 
should be considered if the tumor is >5 mm in thickness 
[150]. In the past, brachytherapy typically consisted of low-
dose irradiation, but today most institutions have replaced 
this practice with high-dose irradiation. According to a 
retrospective study of radiation therapy of vaginal cancer 
using high-dose irradiation, the treatment results, recur-
rence patterns and adverse events are all similar to those 
of low-dose irradiation in the past [149, 177–180]. Current 
evidence does not permit the recommendation of particular 
points for evaluating the dose in brachytherapy or for select-
ing the method of fractionation or dose. However, the typi-
cal regimen is three to six treatments with a dose of 4–7 Gy 
per treatment, taking the entire vaginal mucosa as the CTV 
[150, 151]. External beam irradiation to the clinical focus of 
disease with a dose of 65–70 Gy alone may be performed in 
the following cases—where the tumor has penetrated deeply 
and the boundary is unclear, or if shrinking of the tumor 
using initial external beam irradiation is insufficient and 
the physician judges that the tumor cannot be treated with 
the appropriate dose using brachytherapy, or if the facility 
is not able to perform brachytherapy [141, 152].
In recent years, CCRT has been used in radiation therapy 
for locally advanced vaginal cancer, following the evidence 
of cervical cancer. Several reports examined the efficacy of 
CCRT using drugs such as cisplatin and 5-fluorouracil to 
improve the tumor control rate in locally advanced vaginal 
cancer, but these are only retrospective studies in single institu-
tions, with small sample sizes [143, 181–183]. Because of the 
rarity of this disease, it is difficult to test the efficacy of con-
current chemotherapy through randomized controlled trials. 
For this reason, it is judged appropriate to apply the results of 
clinical trials regarding cervical cancer, based on the similari-
ties of organ site, causal factors and histopathology. Physicians 
must consider concurrent use of chemotherapy in combination 
with radiation therapy if the tumor is stage III or IVA, >4 cm 
in diameter, or positive for lymph node metastasis, and general 
health is good and organ function is preserved [143, 184]. A 
pattern of care analysis in the United States determined that 
the use of CCRT with cisplatin as the main drug has been 
increasing since 1999 [185]. Nonetheless, due caution is in 
order regarding adverse events, given that patient age is typi-
cally higher for vaginal cancer than for cervical cancer [181].
Surgical treatment for invasive vaginal cancer
CQ 13: How should surgical therapy be applied, and what 
methods should be used?
Recommendations
(1) Surgical therapy may be considered in clinical stages I 
and II if the tumor is located in the upper third of the vagina 
(Grade C1).
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(2) Surgical therapies may include radical hysterectomy, or 
modified radical hysterectomy and pelvic lymphadenectomy, 
and vaginectomy with sufficient excision margin (Grade C1).
(3) Pelvic exenteration may also be considered in clinical 
stage IVA disease (Grade C1).
Comments
In 56% of vaginal cancers the tumor is in the upper third of 
the vagina and about half of those are located in the poste-
rior wall. If a tumor extends to the middle or lower third of 
the vagina, it will probably require pelvic exenteration or 
vulvectomy to remove it completely. Because of the sig-
nificant reduction in QOL with such an invasive procedure, 
physicians tend to select radiation therapy. In the case of a 
stage I or II tumor in the upper vagina, a radical or modified 
radical hysterectomy is often selected, in combination with 
vaginectomy with sufficient margin, as is the practice with 
cervical cancer.
In a retrospective examination of 100 cases of primary 
vaginal cancer at a single institution, it was reported that the 
prognosis was better for surgical therapy than for radiation 
therapy alone if the tumor was located in the upper one-third 
of the vagina in clinical stage I or II [186]. A report from 
Japan analyzed 51 cases of vaginal cancer and found a simi-
lar trend [147]. These reports deal only with stage I and II 
cases in which the tumor extends no further than the upper 
third of the vagina. If the tumor is larger, extending beyond 
the upper third, radiation therapy is selected. In the case of 
small tumors localized in the lower vagina, however, surgical 
therapy may be considered. In an analysis of 4885 cases of 
primary vaginal cancer conducted by the US National Can-
cer Database, the 5-year survival rate was found to be 90% 
for surgical therapy and 63% for radiation therapy in stage I; 
in stage II, the figures were 70 and 57%, respectively. These 
figures indicate a much better trend for surgical therapy than 
for radiation therapy with probable selection bias [136, 187].
In histological terms, the majority (79–85%) of vaginal 
cancers are squamous carcinomas, while 6–14% are adeno-
carcinomas [134, 136]. When the type of therapy is selected 
by histological category, stage I and II adenocarcinoma 
(especially clear-cell adenocarcinoma) is poorly sensitive 
to radiation therapy, and surgical therapy is recommended 
[134, 188].
Surgical therapy may consist of vaginectomy preserving 
a sufficient excision margin, radical hysterectomy and pel-
vic lymphadenectomy. Curative surgery for a tumor in the 
lower third of the vagina must be combined with inguinal 
lymphadenectomy. Postoperatively, if risk factors such as a 
positive stump or lymph node metastasis are present, radia-
tion therapy is recommended as an adjuvant therapy [147, 
154, 188].
When vaginal cancer is discovered after a hysterectomy, 
surgical therapy may also be considered if the tumor is local-
ized in the vaginal wall. Partial vaginectomy is conducted 
for carcinoma in situ. For invasive carcinoma in the upper 
third of the vagina, a vaginectomy including paracolpium, 
combined with a pelvic lymphadenectomy is recommended 
[188].
Extended surgery such as pelvic exenteration may be con-
sidered if the patient has the invasive tumor to the rectum 
or urinary bladder, a rectovaginal or vesicovaginal fistula, 
or local recurrent tumors after radiation therapy [134, 188]. 
According to a report by the US National Cancer Database, 
the 5-year survival rate in stage III and IV is 47% for surgical 
therapy alone and 35% for radiation therapy alone. However, 
the 5-year survival rate rises to 60% when surgical and radia-
tion therapy are combined, indicating a favorable trend when 
surgery is added [136]. There should be selection bias not 
to perform surgery for cases with tumors extending to the 
pelvic wall, and to select radiation therapy for highly inva-
sive cases. Consequently, surgery may be performed only for 
cases where the prognosis tends to be better.
Follow-up of vaginal cancer
CQ 14: How should periodic follow-up be handled after 
treatment?
Objective
The objective is to examine appropriate intervals and meth-
ods for periodic follow-up to deal with recurrences and com-
plications associated with treatment.
Recommendations
(1) A rough guide to the intervals for periodic follow-up 
after treatment is as follows (Grade C1):
First and second years: once every 1–3 months
Third to fifth years: once every 6 months
Sixth and subsequent years: once a year
(2) Conduct medical interviews, inspection, palpation, cytol-
ogy, biopsy, chest X-ray examination, tumor markers and 
CT (Grade C1).
Comments
No evidence exists to suggest that diagnosis for recurrence 
through periodic follow-up after treatment for vaginal cancer 
leads to improved prognosis. No reliable research has been 
carried out on the intervals and methods of examination for 
periodic follow-up, and no consensus on these matters has 
been reached.
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The guidelines of the NCI of the United States include 
no recommended interval for periodic follow-up, except that 
cytodiagnosis and image examination should be conducted 
when physical findings lead the physician to suspect recur-
rence, or when the patient reports subjective symptoms 
[189].
According to the American College of Radiology (ACR) 
Appropriateness Criteria, periodic follow-up is recom-
mended once every 3 months for the first 2 years after treat-
ment, followed by periodic observation at longer intervals 
thereafter. However, the grounds for these recommenda-
tions are not explained [190]. Some retrospective studies 
of multiple cases showed 70–80% of relapsing cases occur 
within the first 2 years after initial treatment. The recur-
rence rate declines for the third and subsequent years, but 
recurrences have been confirmed even after 5 years [141, 
142]. While the factor most highly correlated with recur-
rence is stage [143, 148], localized recurrence is the most 
common pattern regardless of stage [141–143, 148]. Recur-
rence in the lymph nodes is also common, with metasta-
sis frequently occurring in the pelvic nodes, and in the 
inguinal nodes when the primary site is in the lower one-
third of the vagina [141]. According to a report on 301 
cases of vaginal cancer that were treated with radiation 
therapy, recurrence was localized in the vagina in 69 cases 
(23%), occurred in the pelvic nodes in 21 cases (7%) and 
the inguinal nodes in 12 cases (4%), while distant metasta-
sis occurred in 44 cases (15%). Prognosis after recurrence 
was extremely poor, with a 5-year survival rate of only 20% 
even for local recurrence. The rate dropped to 4%, indicat-
ing that recovery is extremely difficult after recurrence in 
cases of lymph node recurrence or of distant metastasis 
[141].
Medical interviews, inspection and palpation are vital 
components of medical examinations in periodic follow-
up after treatment. Recurrence can be confirmed using 
cytodiagnosis and biopsy if recurrence is suspected in 
the vagina or superficial lymph nodes. Other examina-
tion items useful in finding recurrences in other locations 
include chest X-ray, tumor markers, CT, MRI and FDG-
PET. However, no standard examinations or schedules have 
been established.
The current first choice for treatment, radiation therapy, is 
associated with long-term complications. The rate of occur-
rence of Grade 3–4 adverse events after radiation therapy is 
reported as 13–17%, and can occur even 10 years after treat-
ment [141, 143]. Frequent complications include radiation 
proctitis, ileus, homorrhagic cystitis, rectovaginal fistula, 
vesicovaginal fistula, gastrointestinal obstruction and ure-
thral stenosis [141, 143]. Because such complications can 
severely damage a patient’s QOL, long-term periodic follow-
up to check for these conditions is vital.
Chapter 4: Treatment strategies for other vulvar 
and vaginal cancers
 General consideration
Malignant diseases occurring in the vulva other than squa-
mous carcinoma include cancers and sarcomas originating 
in the skin, such as Paget’s disease and associated invasive 
carcinomas, malignant melanomas, cancers originating in 
the Bartholin’s glands, and basal-cell carcinomas.
Malignant diseases occurring in the vagina other than 
squamous carcinoma include adenocarcinoma, malignant 
melanomas and sarcomas. Because Paget’s disease and 
malignant melanomas essentially originate in the skin, 
detailed guidelines have already been published for their 
general treatment as diseases of the skin [191]. However, 
gynecologists encounter these two diseases relatively com-
monly as lesions of the vulva and vagina, and conditions 
peculiar to the vulva and vagina must be taken into account 
in their treatment. Standard treatment methods for other 
tumors in the vulva and vagina are not established due to 
their rarity. Physicians must deal with these diseases on a 
case-by-case basis according to the characteristics of each 
tumor and the condition of each patient.
(1) Histopathological approaches
Vulvar Paget’s disease is characterized by intraepithelial 
proliferation of large atypical cells other than the squamous 
epithelium and melanocytes. This disease can be divided 
into two types—primary Paget’s disease, which originates in 
the skin of the vulva; and secondary Paget’s disease, which 
originates from malignancies in surrounding organs such as 
the rectum, anal canal, urinary tract and uterine cervix. Pri-
mary Paget’s disease can be further divided into tumors of 
intraepidermal origin and those originating from cancer of 
skin appendages or the Bartholin’s glands [192]. In second-
ary Paget’s disease, treatment including the primary organ 
must be considered. Histologically, Paget’s cells are larger 
than the surrounding epithelial cells and exist as isolated 
cells or nests with various sizes. Occasionally Paget’s cells 
appear in tubular form or as signet-ring cells. Primary and 
secondary Paget’s disease can be distinguished immunohis-
tochemically. The tumor cells of primary Paget’s disease are 
positive for cytokeratin (CK) 7 and GCDFP-15 but generally 
negative for CK20, while the cells of rectal and anal canal 
carcinomas are CK7-negative, CK20-positive and GCDFP-
15-negative. Urothelial carcinoma cells are both CK7- and 
CK20-positive, and GCDFP-15-negative [193, 194].
Malignant melanomas are malignant tumors of melano-
cytes. Malignant melanomas originating in the vulva and 
vagina are histologically classified into three categories—
mucosal, superficial-spreading and nodular. In the vulva, 
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the mucosal and superficial-spreading types are dominant, 
while the nodular type is common in the vagina [195, 196]. 
In histological diagnosis, positive result in immunostaining 
for S-100 protein, HMB-45, and melan-A support the confir-
mation of melanocytic features. Stage is determined by the 
staging system of cutaneous melanomas [197].
(2) Surgical therapy
Paget’s disease
Vulvar Paget’s disease presents in several forms as previ-
ously mentioned in histological approaches. Physicians need 
to be thoroughly familiar with these various types of Paget’s 
disease when providing treatment (CQ15).
The first choice in treatment of vulvar Paget’s disease 
without invasive carcinoma is wide local excision in due 
consideration of the excision range. The local relapse rate 
after excision is high (32–37%) [198, 199] for at least three 
reasons. First, this disease tends to present with multiple foci 
of disease. Second, foci of disease are sometimes present at 
sites that appear normal at the gross (visible) level. Third, 
the boundaries of tumors can be difficult to distinguish in 
the vulva, due to the region’s natural pigmentation as well as 
conditions such as eczema and inflammation. Fortunately, 
while the high relapse rate often requires repeated treatment, 
intraepithelial lesions transition gently, and prognosis tends 
to be exceptionally favorable [198–201]. Some researchers 
variously advocate performing a biopsy (mapping biopsy) on 
areas around the focus of disease that appear normal preop-
eratively [202] or performing a frozen section examination 
during surgery [203, 204], to confirm that no focus of disease 
remains in the excision stump. However, other reports argue 
that these procedures are not necessarily effective [205, 206].
Surgery is performed in accordance with procedures for 
invasive vulvar cancer if Paget’s disease is accompanied by 
invasive carcinoma. The vulva is the most common site (82%) 
for invasive extramammary Paget’s disease in women accord-
ing to a report on a cohort study [207]. In 1439 cases of inva-
sive extramammary Paget’s disease, the disease-specific 5-year 
survival rate was 95% in cases with localized lesion, 85% for 
lesions advanced to adjacent organs and 53% for distant metas-
tasis. The prognosis was reported to be significantly better for 
the surgery group compared to the non-surgical group.
Malignant melanomas
Vulvar and vaginal malignant melanomas are mucosal. They 
are distinct from cutaneous malignant melanomas, which com-
prise >98% of malignant melanomas. Cutaneous malignant 
melanomas have been treated by surgical therapy and pharma-
cotherapy, based on their clinical and histopathological char-
acteristics. Similarly, thorough surgical excision is a principle 
for malignant melanomas of the vulva and vagina, but restric-
tions exist concerning anatomical difficulties and postoperative 
QOL. Currently, pharmacotherapy is also used, following the 
practice for cutaneous malignant melanomas (CQ16).
A margin of ≥2 cm of normal tissue is generally mandatory 
in excision of vulvar malignant melanomas, but if tumor 
infiltration is ≤1 mm, a margin of ≥1 cm is regarded suf-
ficient [208–210]. Radical vulvectomy is not necessarily 
required, and radical local excision may be applicable, as is 
the case with squamous carcinoma. Even in such cases, the 
subcutaneous adipose tissue should be totally resected just 
above the fascia. Conversely, in cases with more tumor infil-
tration and/or spread, wider excision is usually performed. 
Inguinal lymph node metastasis is a definite poor prognos-
tic factor for vulvar malignant melanomas. Lymphadenec-
tomy (biopsy) is required to confirm the presence of metas-
tasis, but as the therapeutic significance of this procedure 
is obscure [211], SLN biopsy has recently been applied to 
avoid systemic node dissection. This approach is proclaimed 
to have >85% negative predictive value, but the procedure 
remains at the research stage and should be performed only 
by highly experienced teams [212, 213].
Most vaginal malignant melanomas are diagnosed at an 
advanced stage, rendering prognoses extremely poor. 
Extended surgeries such as radical vaginectomy, pelvic exen-
teration, and inguinal and pelvic lymphadenectomy have 
been performed, but the significance of these procedures 
is not conclusive [214, 215]. In small localized cases with 
shallow infiltration, local excision with sufficient margin 
followed by postoperative treatment may provide favorable 
outcomes [216].
Other vulvar cancers
For other vulvar cancers, the most commonly chosen treat-
ment option is surgery, but the procedure needs to be deter-
mined based on the clinical characteristics. For example, as 
tumors originating in Bartholin’s glands tend to infiltrate 
deeper than ordinary vulvar cancers, excision must extend 
deeper in order for curative surgery to be effective [217, 
218]. Because the excision stumps have a high positive rate 
for foci of disease, addition of preoperative and postopera-
tive radiation therapy has been reported, but prognosis is still 
poor [218, 219]. For basal-cell carcinoma, local excision is 
usually judged sufficient because metastasis is rare. How-
ever, a local relapse rate of 10–22% is reported, and caution 
is in order [220].
(3) Radiation therapy
In vulvar Paget’s disease, radiation therapy is applied in 
elderly patients or patients with medical complications 
rendering the condition inoperable, or in advanced disease 
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rendering surgery inappropriate, and in cases of postopera-
tive recurrence. The only reports on the effectiveness of this 
therapy are retrospective studies of a small number of cases 
and case reports. The study with the largest number of cases 
was reported from Japan, consisting of 22 cases of radiation 
therapy for external genital Paget’s disease, including 12 
cases of vulvar Paget’s disease. The treatment results con-
sist of 10 cases of definitive radiation therapy, eight cases 
of postoperative irradiation and four cases of postoperative 
recurrence. The 5-year local control rate for these cases was 
84%, the disease-specific survival rate was 73%, and the 
overall survival rate was 53%, with no serious radiation mor-
bidity [221].
Definitive radiation therapy is rarely the first choice for 
malignant melanomas as their sensitivity to irradiation is 
low. However, heavy-particle radiation therapy has been 
conducted on malignant melanomas on a trial basis in the 
gynecology field, as it has a stronger biological effect than 
conventional radiation therapy. Some effectiveness has 
been reported [222].
As an adjuvant treatment to surgery, postoperative irra-
diation has been conducted in cases of lymph node metasta-
sis, for which the risk of recurrence is high. This procedure 
has been shown to improve the control rate in the lymph 
node area [223, 224]. However, its contribution to improve-
ment of prognosis has not been established, and problems 
of increasing late radiation morbidity have been pointed out. 
The decision on whether to apply these procedures must be 
judged on a case-by-case basis.
 Clinical questions and recommendations
Surgical treatment and alternative therapy for vulvar 
Paget’s disease
CQ 15: What treatments are recommended for primary vul-
var Paget’s disease? (Fig. 5)
Objective
The objective is to examine treatment methods for primary 
vulvar Paget’s disease.
Recommendations
(1) Wide local excision with sufficient excision margin is 
recommended for intraepithelial lesions unaccompanied by 
invasive carcinomas (Grade B).
(2) A mapping biopsy may be considered for lesions without 
a clear gross boundary (Grade C1).
(3) Surgery following the practice for ordinary invasive 
vulvar cancer is recommended for lesions accompanied by 
invasive carcinomas (Grade B).
(4) Radiation therapy may be considered in inoperable cases, 
or in cases of recurrence (Grade C1).
Comments
For intraepithelial vulvar Paget’s disease without inva-
sive carcinoma, the recommended treatment is wide local 
Fig. 5  Primary vulvar Paget’s 
disease
Clinicopathological finding Treatment plan
Clear disease
margins
Resectable ࣭Wide local excision
Unclear disease Mapping
Paget's disease margins biopsy
Intraepithelial disease ࣭Radiation therapy
Not resectable ࣭Follow up࣭Surgery according to
Resectable  vulvar cancer
 (CQ02, 03, 04)
Paget's disease with
invasive disease
Not resectable ࣭Radiation therapy࣭BSC
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excision, giving careful consideration to the excision range. 
The local recurrence rate after excision is reported to be 
as high as 32–37%. However, progression in intraepithe-
lial Paget’s disease is gentle, and its prognosis is extremely 
favorable [198, 199].
No highly reliable evidence exists concerning the exci-
sion range (excision margin) required for the complete exci-
sion of vulvar Paget’s disease. According to the discussion 
of extramammary Paget’s disease in Treatment Guidelines of 
Malignant Skin Tumors, Japan, excision may be conducted 
with a margin of about 1 cm if the focus of disease has a clear 
gross boundary or the site is judged negative for metastasis 
in a mapping biopsy. If the gross boundary is not clear, an 
excision margin of about 3 cm is recommended [191]. These 
recommendations are based on the findings of two studies. 
First, according to data from mapping biopsies of extramam-
mary Paget’s disease and from implementation of Mohs sur-
gery (surgery in which the entire excision stump is confirmed 
during surgery using frozen sections), an excision margin of 
≥3 cm is required for extramammary Paget’s disease. Second, 
in a study of 46 cases in which a margin of 1 cm was obtained 
for lesions with clear gross boundaries on ordinary skin, the 
difference between the gross boundary and the histological 
boundary was small [225, 226]. In a report on 33 cases of 
vulvar Paget’s disease in which frozen section diagnoses were 
conducted during surgery to determine excision range, the 
excision stump was positive in 44% of cases, while in cases 
where these intraoperative diagnoses were not conducted, the 
positive rate was 56% [199]. Another study, reporting on 30 
cases of vulvar Paget’s disease, found that in nine cases where 
the excision range was decided on gross appearance, the posi-
tive rate for the excision stump was 67%, but in 18 cases where 
the excision range was decided based on mapping biopsies and 
intraoperative checks during surgery, the positive rate declined 
to just 39% [202]. Furthermore, in a single-facility retrospec-
tive study in Japan of 18 cases where the excision margin was 
determined so as to ensure a negative mapping biopsy, the 
stump was negative in postoperative histopathological diag-
nosis and no recurrences were confirmed [227]. These results 
testify that mapping biopsies and frozen section checks during 
surgery reduce the positive rate in excision stumps. However, 
other studies found that in cases where excision stumps were 
positive, the recurrence rate was 31–70%, and even when it 
was negative, recurrence was confirmed in 18–38% of cases, 
indicating that recurrence can happen regardless of the condi-
tion of excision stumps [197, 228, 229].
The depth of the excision is sufficient to extend through 
all dermal layers and slightly into the subcutaneous fat 
in cases of intraepithelial lesion because the tissue of the 
vulvar appendages of the skin is only ≤4 mm thick. For 
intraepithelial lesions without invasive carcinomas, inguinal 
lymphadenectomy should not be conducted, as lymph node 
metastasis is absent.
Because vulvar Paget’s disease can progress into adjacent 
structures such as the urethra, vagina and anus, it is neces-
sary to confirm sufficiently that such progression has not 
occurred when setting the excision range. These mucous 
membrane adjacent organs must also be excised as far as 
possible if such progression is confirmed. Within the anus, 
excision is possible as far as the pectinate line.
Although the prognosis for intraepithelial vulvar Paget’s 
disease is favorable, postoperative local recurrence is fre-
quent. According to a report on 17 cases of recurrence out 
of 28 initial surgery cases, one to three additional excisions 
were performed in 14 of the 17 recurrence cases, and the 
lesions were eliminated in 80% of these cases [229].
Whether for initial treatment or for recurrence treatment, 
surgical excision should be considered first. However, as 
patients are typically elderly, averaging 68–70 years of age 
at the time of diagnosis, the focus of disease is often wide. 
For this reason, a less invasive treatment has come to be 
adopted, in which photodynamic therapy (PDT), external 
use of imiquimod, or laser vaporization, are tried alone or 
in combination [230–232]. However, the reports on these 
treatment methods consist mainly of retrospective studies 
and case reports, and the observation period is often brief. 
No randomized controlled trials have been performed to 
compare the recurrence rate and survival rates of these con-
servative treatments to those of surgical excision. At present, 
it is not possible to recommend these procedures for daily 
practice.
When intraepithelial Paget’s disease is combined with 
invasive carcinoma, surgery is performed as for normal 
invasive vulvar cancer. Recommended therapies include 
local excision with securing an excision margin of ≥1 cm, 
or radical vulvectomy, with inguinal lymphadenectomy. 
No data exist to suggest that inguinal lymphadenectomy 
improves survival rate if the condition is combined with 
invasive carcinoma. However, a report on 76 cases of vulvar 
Paget’s disease including 22 cases accompanied by invasive 
carcinoma reported that biopsy or excision of the inguinal 
lymph nodes was conducted in 19 cases and metastasis to the 
inguinal lymph nodes was confirmed in nine of these cases, 
six of which resulted in death [200]. Because the inguinal 
lymph nodes are a common site for metastasis, and lymph 
node metastasis is an important prognostic factor, dissec-
tion should be considered in cases with underlying invasive 
cancer.
No standard treatment method is established for invasive 
vulvar Paget’s disease with metastasis, or recurrent disease. 
No randomized controlled trials or prospective trials have 
been reported regarding the use of postoperative radiation 
therapy in cases of vulvar Paget’s disease combined with 
invasive carcinoma or metastasis to the inguinal lymph 
nodes, and the usefulness of the treatment is difficult to 
assess at this point. Similarly, no regimen of chemotherapy 
226 Int J Clin Oncol (2018) 23:201–234
1 3
is suitable for recommendation in the case of advanced vul-
var Paget’s disease with distant metastasis. A small number 
of reports exist for single-drug or multi-drug chemotherapy 
following the practice for breast cancer or gastrointestinal 
cancer. However, the response rate and survival benefit still 
remain unclear.
If surgery is impossible due to advanced age, medical 
complications or progressive disease, or if postoperative 
recurrence occurs and no other treatments are available, 
radiation therapy may be considered. One report from Japan 
details the results of radiation therapy in 22 cases of Paget’s 
disease in the external genitalia as previously cited [221]. 
X-rays or electron beams were used for radiation therapy, 
and effort was made to irradiate the entire focus of disease 
with a uniform dose. If invasion is confirmed from the der-
mis to the hypodermis, the danger of lymph node metastasis 
exists, and preventive irradiation of the lymph node area may 
be considered [233]. Although no standard dose fractiona-
tion is established, the required total dose is believed to be 
50 Gy for non-invasive cases and 55–65 Gy for invasive 
cases and cases combined with invasive adenocarcinoma, 
with 1.8–2 Gy fraction [221, 233]. For very elderly patients, 
periodic follow-up alone is another option in vulvar Paget’s 
disease not accompanied by invasive carcinoma.
Treatment of malignant melanoma of the vulva and vagina
CQ 16: What treatments are recommended for malignant 
melanomas?
Objective
The objective is to exhibit appropriate treatments for vulvar 
and vaginal malignant melanomas.
Recommendations
(1) Excision of the primary lesion is recommended if distant 
metastasis is not confirmed. (Grade B).
(2) SLN biopsy with cooperation of dermatologists may be 
useful for determining the disease stage (Grade C1).
(3) Dacarbazine-based chemotherapy may be considered. 
(Grade C1).
Comments
The tumor thickness (TT) of the primary lesion is the most 
significant prognostic factor for vulvar malignant melanomas 
[211]. Because the TT is correlated with degree of progres-
sion of the tumor, the excision range should be decided in a 
two-step manner after evaluating the TT. Namely, excisional 
biopsy is initially performed with entire layers of subcuta-
neous adipose tissue above the basal fascia taking a 2-mm 
margin around the primary lesion [191]. A partial resection 
is acceptable if the lesion is too large or too close to the ure-
thral opening to suture the wound defect since difference in 
prognostic outcome exists although the diagnostic accuracy 
is decreased [191]. Based on tumor histology and TT, the 
additional excision range is decided as follows —the mar-
gin from the tumor border should be set at 3–5 mm, 1 cm, 
and 2 cm for in situ lesions, TT ≤ 2 mm, and TT > 2 mm, 
respectively [191, 234]. As survival prognosis cannot be 
improved even with wider excision [195, 235], the excision 
range should be addressed near to the urethral opening and 
anus with careful consideration of postoperative QOL. The 
prognostic outcome is not worsened by the interval between 
the primary excision and the second excision, and is supe-
rior in two-step excision after confirming the TT to one-step 
wide-area excision [191].
For vaginal malignant melanomas, curative excision is 
also preferred; however, a pelvic exenteration is frequently 
necessary due to the tumor location and multiple foci. 
Because no difference in prognosis exists between highly 
radical surgery and local excision, a combination of local 
excision with irradiation would be preferred both for less 
complications and better local control and survival [236].
In vulvar malignant melanomas, those with regional 
lymph node metastasis exhibit poor prognostic outcome, 
but lymph node metastasis does not in itself comprise an 
independent prognostic factor [211]. The significance of 
systematic lymphadenectomy is low as it did not provide 
better prognostic outcome even with radical vulvectomy 
compared to wide local excision alone [237, 238]. Curative 
lymphadnectomy may be considered to provide long-term 
survival for young patients who bear only a couple of lymph 
node metastasis without extracapsular invasion [191]. As for 
vaginal malignant melanomas which are accompanied with 
lymph node metastasis even at early stages, the significance 
of systematic lymphadenectomy on prognosis is still unclear.
SLN biopsy is so far a case-trial procedure for vulvar and 
vaginal malignant melanomas [239]. As an SLN biospy is 
expected to detect and excise microscopic metastasis, it is 
already recommended for those bearing cutaneous malignant 
melanomas with 1–4 mm thickness due to its safety and 
efficacy [191]. A phase III trial also exhibited that a 10-year 
disease-free survival rate for those with TT >1.2 mm was 
significantly higher if an SLN biopsy was performed [240]. 
Thus, the SLN biopsy, supervised by a certified derma-
tologist with experience in treating malignant skin tumors, 
would be reasonably applied to the treatment for vulvar and 
vaginal malignant melanomas.
Postoperative adjuvant treatment is widely performed 
for vulvar and vaginal malignant melanomas although its 
efficacy has not been well clarified. DAV-Feron therapy 
is a three-drug combination chemotherapy of dacarbazine 
(DTIC), nimustine and vincristine combined with a local 
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injection of interferon-beta, and it has been employed in 
Japan as a prognosis-improving regimen for high-risk cuta-
neous malignant melanomas [241]. Postoperative immu-
notherapy (interferon-alpha and interleukin) can reduce 
recurrence but its survival benefit is uncertain [191]. In 
applying these regimens on vulvar and vaginal malignant 
melanomas, supervision by well-experienced dermatologists 
is mandatory.
The efficacy of postoperative irradiation to prevent node 
relapse of cutaneous malignant melanoma is demonstrated 
not only in retrospective studies [223] but a randomized 
controlled trial (ANZMTG 01. 02/TROG 02. 01) [242]. 
However, whether to conduct irradiation or not should be 
determined for each case by evaluating the risk of recurrence 
since postoperative irradiation is highly accompanied with 
adverse events such as lymphedema and because its contri-
bution to better survival is not clear. Hypofractionation using 
brief exposure of high doses per treatment is expected to be 
safe and effective against malignant melanomas, although 
there is no standard regimen established to date.
The prognostic outcome of patients bearing distant metas-
tasis is so poor that extensive excision should be avoided. 
Excision of metastasis is preferred only for those bearing 
a solitary tumor with good performance status. Irradiation 
to metastases in bones or central nerves relieves symptoms 
in half of cases, and stereotactic irradiation reduces tumor 
growth by 90% even for multiple brain metastases without 
active foci other than the brain [191].
Systemic chemotherapy using DTIC is applied on those 
bearing metastasis, but the response rate is only 20% and the 
long-term CR rate is <2% [191]. The initial response rate 
of DTIC is higher with other anti-cancer drugs compared to 
DTIC alone. However, there is no randomized trial which 
demonstrates the superiority of survival period of DTIC-
combination therapy to DTIC alone.
For advanced malignant melanomas, several systemic 
immunotherapies have been investigated—adoptive cellular 
immunotherapy, cancer vaccines, and cytokine treatments 
such as interferon-alpha and interleukin-2. The response 
rates of these treatments, however, remain at most 10% 
[191]. Recently, much attention has been paid to immune-
checkpoint targeting drugs (anti-CTLA-4 antibodies and 
anti-PD-1 antibodies) [243, 244] and to molecular-targeting 
drugs for tumor-specific genetic mutations. An anti-PD-1 
antibody, nivolumab, and an anti-CTLA-4 antibody, ipili-
mumab, would deliver longer survival to cutaneous malig-
nant melanomas, and other immune-checkpoint targeting 
drugs used overseas are also expected to be available in 
the near future. However, at present it is well demarcated 
that pharmacotherapies are tailored to mucosal-type vul-
var and vaginal malignant melanomas, in which no stand-
ard treatments have been established. A multi-institutional 
prospective study should be conducted to assess the efficacy 
of these drugs on rare mucosal malignant melanomas includ-
ing vulvar and vaginal malignant melanomas.
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